

Customer No. 000959

Case Docket No. MNI-061

THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231"Express Mail" Mailing Label Number EL008485818USDate of Deposit October 19, 1998

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Signature

Viriato Cardoso

Please Print Name of Person Signing

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Rory A.J. Curtis and M. Alexandra Glucksmann
For: ISOLATED PROTEINS AND NUCLEIC ACID MOLECULES HAVING HOMOLOGY
TO THE NIP2 PROTEIN AND USES THEREOF

Enclosed are:

- ☐ This is a request for filing a ☐ continuation ☐ divisional application under 37 CFR 1.53(b), of pending prior application serial no. _____ filed on _____ entitled _____.
- ☒ 94 pages of specification (including 17 pages of sequence listing), 4 pages of claims, 1 page of abstract.
- ☒ 16 sheets of informal drawings (Figures 1-12).
- ☒ An unexecuted Declaration, Petition and Power of Attorney.
- ☒ Transmittal Letter for Diskette of Sequence Listing.
- ☒ Diskette Containing Sequence Listing.
- ☐ Other _____

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE	////////////////////	
TOTAL CLAIMS	66 - 20	= 46
INDEP. CLAIMS	6 - 3	= 3
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

* If the difference in Col. 2 is less than zero,
enter "0" in Col. 2.

SMALL ENTITY	
RATE	FEE
////////	\$
x 11=	\$
x 41	\$
+135	\$
TOTAL	0

OTHER THAN SMALL ENTITY	
RATE	FEE
////////	\$ 790.00
x 22=	\$1012.00
x 82	\$ 246.00
+270	\$ 270.00
TOTAL	\$2318.00

- ☐ Please charge my Deposit Account No. 12-0080 in the amount of \$.
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-0080.
A duplicate copy of this sheet is enclosed.
- ☐ Any additional filing fees required under 37 C.F.R. 1.16.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.

10/19/98
JC511 U.S. PTO

JC511 U.S. PTO
09/17/98
86/61/01


09434937 4115933

- ☐ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 12-0080.
A duplicate copy of this sheet is enclosed.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).
- ☐ Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.
- ☐ A check in the amount of \$ _____ to cover the recording of assignment documents is also enclosed.
- ☒ Address all future communications (May only be completed by applicant, or attorney or agent of record) to Amy E. Mandragouras at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

Date: October 19, 1998

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By 
Amy E. Mandragouras
Reg. No. 36,207
28 State Street
Boston, MA 02109
(617) 227-7400
Telecopier (617) 742-4214

ISOLATED PROTEINS AND NUCLEIC ACID MOLECULES HAVING HOMOLOGY TO THE NIP2 PROTEIN AND USES THEREOF

5

Background of the Invention

Apoptosis or programmed cell death is an essential physiological process of selective elimination of cells in multicellular organisms. This process is invoked during normal organ development and tissue homeostasis and also during certain pathological conditions that result in degenerative diseases. Programmed cell death plays an important role in regulating the multiplication of and pathogenesis by a number of viruses. In virus-infected cells, apoptotic paradigms are initiated as a cellular defensive mechanism to eliminate infected cells. However, a number of viruses encode proteins that suppress apoptosis resulting in efficient viral replication and pathogenesis. Human adenoviruses have evolved multiple strategies employing proteins coded by three different gene blocks, E1B, E3, and E4 to overcome the effect of apoptosis of infected permissive cells. One of the proteins coded by the E1B region, the 19K protein confers a survival function in adenovirus-infected cells and prevents premature cell death. Adenovirus mutants defective in the 19K gene produced large clear plaques on infected cell monolayers. Several of these mutants induce an enhanced cytopathic effect in infected cells resulting in cellular destruction as well as fragmentation of cellular and viral DNA. The DNA fragmentation induced by 19K mutants is reminiscent of that observed during apoptosis. Although it has not yet been determined whether DNA fragmentation induced by 19K mutants occurs by an apoptotic mechanism, it is clear that the 19 kDa protein protects against a cell death program induced by viral infection, thus facilitating efficient virus replication. In addition, the 19 kDa protein suppresses the cytotoxic effects of certain external stimuli such as the tumor necrosis factor α and anti-Fas antibody. Both of these agents cause cell death through apoptosis. Similarly, the 19 kDa protein protects cells against the effects of DNA-damaging agents such as the anti-cancer drug cisplatin and ultraviolet radiation induced cell death through a p53-dependent apoptotic pathway. Cells expressing the 19 kDa protein efficiently suppress cell death induced by overexpression of p53. Thus, the 19 kDa protein provides a survival function in virus-infected cells and also protects cells against certain other death-inducing stimuli.

The survival function provided by E1B 19K is similar to the activity of the cellular protooncogene Bcl-2. The Bcl-2 oncogene was isolated from a follicular lymphoma and has been shown to enhance the survival of hematopoietic B and T cells by blocking apoptosis. In addition, overexpression of Bcl-2 protein inhibits apoptosis induced by exposure to diverse stimuli possibly through different pathways. Although the effect of 19 kDa protein

expression on cell death induced by diverse stimuli has not been extensively examined, the Bcl-2 protein can clearly substitute for the 19 kDa protein during adenovirus infection. Characteristic fragmentation of cellular DNA induced by infection with adenovirus type 2 (Ad2) 19K mutants is efficiently suppressed in cells ectopically expressing the human Bcl-2 protein. Similarly, expression of Bcl-2 by an Ad2-Bcl-2 recombinant virus (Ad-Bcl2) can fully substitute for the 19K function. The Ad-Bcl2 virus does not induce DNA fragmentation in infected cells and forms small plaques on cell monolayers. Rao et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:7742-46 have reported that Bcl-2 can substitute for 19K in transformation of primary rat kidney cells in cooperation with E1A. Although these results do not clarify whether the 19 kDa and Bcl-2 proteins function by similar mechanisms, they indicate that these two proteins can provide cell survival function against certain stimuli.

The mechanism by which the 19K gene and the Bcl-2 protooncogene protect against cell death is not known. These proteins may mediate cell survival by interacting with certain cellular proteins. Boyd J.M. et al. (1994) *Cell* 79:341-351, have identified three proteins, NIP1, NIP2, and NIP3, which interact with both the adenovirus E1B 19 kDa protein and the Bcl-2 protein. The NIP1, NIP2, and NIP3 proteins are believed to play a role in the ability of the E1B 19 kDa protein to provide a cell survival function.

Summary of the Invention

The present invention is based, at least in part, on the discovery of novel NIP2 family members, referred to herein as "NIP2b, NIP2cL, and NIP2cS" nucleic acid and protein molecules. The NIP2b, NIP2cL, and NIP2cS molecules of the present invention are useful as modulating agents for regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding NIP2b, NIP2cL, and NIP2cS proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of NIP2b, NIP2cL, and NIP2cS-encoding nucleic acids.

In one embodiment, a NIP2b, NIP2cL, or NIP2cS nucleic acid molecule of the invention is at least 59%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ ID NO:1, 3, 4, 6, 7, or 9 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a complement thereof.

In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO:1 or 3, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID NO:3 and nucleotides 1-369 of SEQ ID NO:1. In another embodiment, the nucleic acid molecule includes SEQ ID NO:3 and nucleotides 1483-3076 of SEQ ID NO:1. In another preferred embodiment, the nucleic

acid molecule consists of the nucleotide sequence shown in SEQ ID NO:1 or 3. In another preferred embodiment, the nucleic acid molecule includes a fragment of at least 535 nucleotides (e.g., 535 contiguous nucleotides) of the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.

5 In another preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO:4 or 6, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID NO:6 and nucleotides 1-22 of SEQ ID NO:4. In another embodiment, the nucleic acid molecule includes SEQ ID NO:6 and nucleotides 989-4235 of SEQ ID NO:4. In another preferred embodiment, the nucleic acid
10 molecule consists of the nucleotide sequence shown in SEQ ID NO:4 or 6. In another preferred embodiment, the nucleic acid molecule includes a fragment of at least 3225 nucleotides (e.g., 3225 contiguous nucleotides) of the nucleotide sequence of SEQ ID NO:4, SEQ ID NO:6, or a complement thereof.

In a preferred embodiment, the isolated nucleic acid molecule includes the
15 nucleotide sequence shown SEQ ID NO:7 or 9, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID NO:9 and nucleotides 1-55 of SEQ ID NO:7. In another embodiment, the nucleic acid molecule includes SEQ ID NO:9 and nucleotides 434-2966 of SEQ ID NO:7. In another preferred embodiment, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID NO:7 or 9. In another
20 preferred embodiment, the nucleic acid molecule includes a fragment of at least 461 nucleotides (e.g., 461 contiguous nucleotides) of the nucleotide sequence of SEQ ID NO:7, SEQ ID NO:9, or a complement thereof.

In another embodiment, a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence
25 sufficiently homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In a preferred embodiment, a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more
30 homologous to the entire length of the amino acid sequence of SEQ ID NO:2, 5, or 8 or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number _____.

In another preferred embodiment, an isolated nucleic acid molecule encodes the amino acid sequence of human NIP2b, NIP2cL, and NIP2cS. In yet another preferred
35 embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:2, 5, or 8 or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In yet another preferred embodiment, the nucleic acid molecule is at least 461,

Sequence of NIP2b, NIP2cL, and NIP2cS

535, or 3225 nucleotides in length. In a further preferred embodiment, the nucleic acid molecule is at least 461, 535, or 3225 nucleotides in length and encodes a protein having a NIP2b, NIP2cL, and NIP2cS activity (as described herein).

Another embodiment of the invention features nucleic acid molecules, preferably
5 NIP2b, NIP2cL, and NIP2cS nucleic acid molecules, which specifically detect NIP2b, NIP2cL, and NIP2cS nucleic acid molecules relative to nucleic acid molecules encoding non-NIP2b, non-NIP2cL, and non-NIP2cS proteins. For example, in one embodiment, such a nucleic acid molecule is at least 300-350, 350-400, 400-450, 461, 461-500, 535, 535-600 or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid
10 molecule comprising the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number_____, or a complement thereof.

In preferred embodiments, the nucleic acid molecules are at least 15 (e.g., contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-
15 348, 431-478, 676-784, 1538-1546, 1587-1598, 1615-1727, or 2070-3076 of SEQ ID NO:1. In other preferred embodiments, the nucleic acid molecules comprise nucleotides 1-348, 431-478, 676-784, 1538-1546, 1587-1598, 1615-1727, or 2070-3076 of SEQ ID NO:1.

In other preferred embodiments, the nucleic acid molecules are at least 15 (e.g., contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-
20 16 of SEQ ID NO:4. In other preferred embodiments, the nucleic acid molecules comprise nucleotides 1-16 of SEQ ID NO:4.

In yet other preferred embodiments, the nucleic acid molecules are at least 15 (e.g., contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-
25 26, 406-598, 1058-2703, 2775-2936, or 2956-2966 of SEQ ID NO:7. In other preferred embodiments, the nucleic acid molecules comprise nucleotides 1-26, 406-598, 1058-2703, 2775-2936, or 2956-2966 of SEQ ID NO:7.

In other preferred embodiments, the nucleic acid molecule encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 5, or 8 or an amino acid sequence encoded by the DNA insert of the plasmid
30 deposited with ATCC as Accession Number_____, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, 4, 6, 7, or 9 under stringent conditions.

Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule, e.g., the coding
35 strand of a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule.

Another aspect of the invention provides a vector comprising a NIP2b, a NIP2cL, or a NIP2cS nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell containing a

Sequence Listing

vector of the invention. In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing a protein, preferably a NIP2b, NIP2cL, and NIP2cS protein, by culturing in a suitable medium, a host cell, e.g., a mammalian host cell such as a non-human mammalian cell, of the invention containing a recombinant expression vector, such that the protein is produced.

Another aspect of this invention features isolated or recombinant NIP2b, NIP2cL, and NIP2cS proteins and polypeptides. In one embodiment, the isolated protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one transmembrane domain. In a preferred embodiment, the isolated protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one calcium binding domain. In yet another preferred embodiment, the isolated protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one "4 transmembrane segment integral membrane protein domain". In a preferred embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one transmembrane domain and has an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8 or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In another embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one calcium-binding domain and has an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8 or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In yet another preferred embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one "4 transmembrane segment integral membrane protein domain" and has an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8 or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In another preferred embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one transmembrane domain and plays a role in apoptosis or programmed cell death. In another embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one calcium-binding domain and plays a role in apoptosis or programmed cell death. In yet another preferred embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one "4 transmembrane segment integral membrane protein domain" and plays a role in apoptosis or programmed cell death. In yet another preferred embodiment, the protein, preferably a NIP2b, NIP2cL, and NIP2cS protein, includes at least one transmembrane domain and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid

molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9. In another embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one calcium-binding domain and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid

5 molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9. In yet another preferred embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, includes at least one "4 transmembrane segment integral membrane protein domain" and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide
10 sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9.

In another embodiment, the invention features fragments of the protein having the amino acid sequence of SEQ ID NO:2, 5, or 8, wherein the fragment comprises at least 15 amino acids (e.g., contiguous amino acids) of the amino acid sequence of SEQ ID NO:2, 5, or 8 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with the
15 ATCC as Accession Number _____. In another embodiment, the protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, has the amino acid sequence of SEQ ID NO:2, 5, or 8, respectively.

In another embodiment, the invention features an isolated protein, preferably a NIP2b, NIP2cL, and NIP2cS protein, which is encoded by a nucleic acid molecule
20 consisting of a nucleotide sequence at least about 59%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to a nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or a complement thereof. This invention further features an isolated protein, preferably a NIP2b, NIP2cL, or NIP2cS protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent hybridization
25 conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or a complement thereof.

The proteins of the present invention or portions thereof, e.g., biologically active portions thereof, can be operatively linked to a non-NIP2b, non-NIP2cL, or non-NIP2cS polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. The
30 invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind proteins of the invention, preferably NIP2b, NIP2cL, and NIP2cS proteins. In addition, the NIP2b, NIP2cL, and NIP2cS proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

35 In another aspect, the present invention provides a method for detecting the presence of a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule, protein or polypeptide in a biological sample by contacting the biological sample with an agent capable of detecting a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule, protein or polypeptide such that the

presence of a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule, protein or polypeptide is detected in the biological sample.

In another aspect, the present invention provides a method for detecting the presence of NIP2b, NIP2cL, and NIP2cS activity in a biological sample by contacting the biological
5 sample with an agent capable of detecting an indicator of NIP2b, NIP2cL, and NIP2cS activity such that the presence of NIP2b, NIP2cL, and NIP2cS activity is detected in the biological sample.

In another aspect, the invention provides a method for modulating NIP2b, NIP2cL, and NIP2cS activity comprising contacting a cell capable of expressing NIP2b, NIP2cL, and
10 NIP2cS with an agent that modulates NIP2b, NIP2cL, and NIP2cS activity such that NIP2b, NIP2cL, and NIP2cS activity in the cell is modulated. In one embodiment, the agent inhibits NIP2b, NIP2cL, and NIP2cS activity. In another embodiment, the agent stimulates NIP2b, NIP2cL, and NIP2cS activity. In one embodiment, the agent is an antibody that specifically binds to a NIP2b, NIP2cL, and NIP2cS protein. In another embodiment, the
15 agent modulates expression of NIP2b, NIP2cL, and NIP2cS by modulating transcription of a NIP2b, NIP2cL, and NIP2cS gene or translation of a NIP2b, NIP2cL, and NIP2cS mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of a NIP2b, NIP2cL, and NIP2cS mRNA or a NIP2b, NIP2cL, and NIP2cS gene.

In one embodiment, the methods of the present invention are used to treat a subject
20 having a disorder characterized by aberrant NIP2b, NIP2cL, and NIP2cS protein or nucleic acid expression or activity by administering an agent which is a NIP2b, NIP2cL, and NIP2cS modulator to the subject. In one embodiment, the NIP2b, NIP2cL, and NIP2cS modulator is a NIP2b, NIP2cL, and NIP2cS protein. In another embodiment the NIP2b, NIP2cL, and NIP2cS modulator is a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule. In
25 yet another embodiment, the NIP2b, NIP2cL, and NIP2cS modulator is a peptide, peptidomimetic, or other small molecule. In a preferred embodiment, the disorder characterized by aberrant NIP2b, NIP2cL, and NIP2cS protein or nucleic acid expression is a disorder characterized by deregulated programmed cell death.

The present invention also provides a diagnostic assay for identifying the presence or
30 absence of a genetic alteration characterized by at least one of (i) aberrant modification or mutation of a gene encoding a NIP2b, NIP2cL, and NIP2cS protein; (ii) mis-regulation of the gene; and (iii) aberrant post-translational modification of a NIP2b, NIP2cL, and NIP2cS protein, wherein a wild-type form of the gene encodes a protein with a NIP2b, NIP2cL, and
35 NIP2cS activity.

In another aspect the invention provides a method for identifying a compound that binds to or modulates the activity of a NIP2b, NIP2cL, and NIP2cS protein, by providing an indicator composition comprising a NIP2b, NIP2cL, and NIP2cS protein having NIP2b,

Patent Application No. 10/100,000

NIP2cL, and NIP2cS activity, contacting the indicator composition with a test compound, and determining the effect of the test compound on NIP2b, NIP2cL, and NIP2cS activity in the indicator composition to identify a compound that modulates the activity of a NIP2b, NIP2cL, and NIP2cS protein.⁸⁸

5

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

- 10 *Figure 1* depicts the cDNA sequence and predicted amino acid sequence of human NIP2b. The nucleotide sequence corresponds to nucleic acids 1 to 3076 of SEQ ID NO:1. The amino acid sequence corresponds to amino acids 1 to 371 of SEQ ID NO: 2. The coding region without the 5' and 3' untranslated regions of the human NIP2b gene is shown in SEQ ID NO:3.
- 15 *Figure 2* depicts the cDNA sequence and predicted amino acid sequence of human NIP2cL. The nucleotide sequence corresponds to nucleic acids 1 to 4235 of SEQ ID NO:4. The amino acid sequence corresponds to amino acids 1 to 322 of SEQ ID NO: 5. The coding region without the 5' and 3' untranslated regions of the human NIP2cL gene is shown in SEQ ID NO:6.
- 20 *Figure 3* depicts the cDNA sequence and predicted amino acid sequence of human NIP2cS. The nucleotide sequence corresponds to nucleic acids 1 to 2966 of SEQ ID NO:7. The amino acid sequence corresponds to amino acids 1 to 126 of SEQ ID NO: 8. The coding region without the 5' and 3' untranslated regions of the human NIP2cS gene is shown in SEQ ID NO:9.
- 25 *Figure 4* depicts a structural, hydrophobicity, and antigenicity analysis of the human NIP2b protein.
- Figure 5* depicts a structural, hydrophobicity, and antigenicity analysis of the human NIP2cL protein.
- Figure 6* depicts a structural, hydrophobicity, and antigenicity analysis of the human
- 30 NIP2cS protein.
- Figure 7* depicts the results of a search which was performed against the HMM database and which resulted in the identification of a "4 transmembrane segments integral membrane proteins" domain in the human NIP2b protein.
- Figure 8* depicts the results of a search which was performed against the HMM
- 35 database and which resulted in the identification of a calreticulin calcium-binding domain in the human NIP2cL protein.

Figure 9 depicts the results of a search which was performed against the HMM database and which resulted in the identification of a calreticulin calcium-binding domain in the human NIP2cS protein.

Figure 10 depicts an alignment of the NIP2b protein with the human Bcl-2/adenovirus E1B 19kDa-interacting protein 2 (BNIP-2, Accession Number U15173) using the GAP program in the GCG software package (Blossom 62 matrix) and a gap weight of 12 and a length weight of 4.

Figure 11 depicts an alignment of the NIP2b protein with the NIP2cL protein using the GAP program in the GCG software package (Blossom 62 matrix) and a gap weight of 12 and a length weight of 4.

Figure 12 depicts an alignment of the NIP2cL protein with the human Bcl-2/adenovirus E1B 19kDa-interacting protein 2 (BNIP-2, Accession Number U15173) using the GAP program in the GCG software package (Blossom 62 matrix) and a gap weight of 12 and a length weight of 4.

Detailed Description of the Invention

The present invention is based, at least in part, on the discovery of novel NIP2 family members, referred to herein as "NIP2b, NIP2cL, and NIP2cS" nucleic acid and protein molecules. These molecules comprise a family of molecules having certain conserved structural and functional features. The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin. Members of a family may also have common functional characteristics.

For example, the family of NIP2b, NIP2cL, and NIP2cS proteins comprise a "transmembrane domain." As used herein, the term "transmembrane domain" includes an amino acid sequence of about 15 amino acid residues in length which spans the plasma membrane. More preferably, a transmembrane domain includes about at least 20, 25, 30, 35, 40, or 45 and spans the plasma membrane. Transmembrane domains are rich in hydrophobic residues, and typically have an α -helical structure. In a preferred embodiment, at least 50%, 60%, 70%, 80%, 90%, 95% or more of the amino acids of a transmembrane domain are hydrophobic, e.g., leucines, isoleucines, tyrosines, or tryptophans. Transmembrane domains are described in, for example, Zagotta W.N. et al, (1996) *Annual Rev. Neurosci.* 19: 235-63, the contents of which are incorporated herein by reference.

Amino acid residues 183-199 of the human NIP2b and amino acid residues 174-190 of the human NIP2cL comprise transmembrane domains.

In another embodiment, a NIP2b, NIP2cL, and NIP2cS of the present invention is identified based on the presence of a "calcium-binding domain" in the protein or

5 corresponding nucleic acid molecule. As used herein, the term "calcium-binding domain" includes a protein domain having an amino acid sequence of about 110 amino acids which has the capacity to bind calcium. Preferably, a calcium binding domain includes a protein domain which is at least 50, 60, 70, 80, 90, or 100 amino acid residues in length and which has the capacity to bind calcium. The calcium-binding domain HMM has been assigned the
10 PFAM Accession MILPAT0063 (<http://genome.wustl.edu/Pfam/WWWdata/EGF.html>).

To identify the presence of a calcium-binding domain in a NIP2b, NIP2cL, or NIP2cS protein, and make the determination that a protein of interest has a particular profile, the amino acid sequence of the protein is searched against a database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters
15 (http://www.sanger.ac.uk/Software/Pfam/HMM_search). For example, the hmmsf program, which is available as part of the HMMER package of search programs, is a family specific default program for MILPAT0063 and a score of 15 is the default threshold score for determining a hit. Alternatively, the threshold score for determining a hit can be lowered (e.g., to 8 bits). A description of the Pfam database can be found in Sonhammer *et al.*
20 (1997) *Proteins* 28(3)405-420 and a detailed description of HMMs can be found, for example, in Gribskov *et al.* (1990) *Meth. Enzymol.* 183:146-159; Gribskov *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.* (1994) *J. Mol. Biol.* 235:1501-1531; and Stultz *et al.* (1993) *Protein Sci.* 2:305-314, the contents of which are incorporated herein by reference. A search was performed against the HMM database resulting in the
25 identification of a calcium-binding domain in the amino acid sequence of NIP2cL (SEQ ID NO: 5) at about residues 55-160 of SEQ ID NO:5 and NIP2cS (SEQ ID NO:8) at about residues 59-96 of SEQ ID NO:8. The results of the searches are set forth in Figures 8 and 9, respectively.

Accordingly, NIP2b, NIP2cL, and NIP2cS proteins having at least 50-60%
30 homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a calcium binding domain of human NIP2cL and NIP2cS are within the scope of the invention.

In another embodiment, a NIP2b, NIP2cL, and NIP2cS of the present invention is identified based on the presence of a "4 transmembrane segment integral membrane protein
35 domain" in the protein or corresponding nucleic acid molecule. As used herein, the term "4 transmembrane segment integral membrane protein domain" includes a protein domain having an amino acid sequence of about 50 amino acid residues and having a bit score for the alignment of the sequence to the "4 transmembrane segment integral membrane protein

domain" (HMM) of at least 1 or greater. Preferably the term "4 transmembrane segment integral membrane protein domain" includes a protein domain having an amino acid sequence of about 60, 70, 80, or 90 amino acids and having a bit score for the alignment of the sequence to the "4 transmembrane segment integral membrane protein domain" (HMM) of at least 2, preferably 3-10, more preferably 10-30, more preferably 30-50, even more preferably 50-75, 75-100, 100-200 or greater. The "4 transmembrane segment integral membrane protein domain" HMM has been assigned the PFAM Accession PF00335 (<http://genome.wustl.edu/Pfam/WWWdata/EGF.html>). A search was performed against the HMM database, as described herein, resulting in the identification of a "4 transmembrane segment integral membrane protein domain" in the amino acid sequence of NIP2b (SEQ ID NO:2) at about residues 253 to 293. The results of the search are set forth in Figure 7.

Accordingly, NIP2b, NIP2cL, and NIP2cS proteins having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a "4 transmembrane segment integral membrane protein domain" of human NIP2b, are within the scope of the invention.

The NIP2b, NIP2cL, and NIP2cS proteins of the present invention are believed to play a role in apoptosis or programmed cell death. As used herein, "programmed cell death" or "apoptosis" includes a genetically regulated process involved in the normal development of multicellular organisms. This process occurs in cells destined for removal in a variety of normal situations, including larval development of the nematode *c. elegans*, insect metamorphosis, development in mammalian embryos including the nephrogenic zone in the developing kidney, and regression or atrophy (e.g., in the prostate after castration). Programmed cell death can occur following the withdrawal of growth and trophic factors in many cells, nutritional deprivation, hormone treatment, ultraviolet irradiation, and exposure to toxic and infectious agents including reactive oxygen species and phosphatase inhibitors, e.g., okadaic acid, calcium ionophores, and a number of cancer chemotherapeutic agents. For a detailed description of programmed cell death see Trump B.F. et al. (1995) *FASEB J.* 9: 219-228 and Lee S. (1993) *Curr. Opin. Cell Biol.* 5: 286-291, the contents of which are incorporated herein by reference. Thus, the NIP2b, NIP2cL, and NIP2cS proteins by participating in a programmed cell death pathway, can modulate a programmed cell death pathway activity and provide novel diagnostic targets and therapeutic agents for disorders characterized by deregulated programmed cell death, particularly in cells that express NIP2b, NIP2cL, and NIP2cS, e.g., neuronal cells.

As used herein, a "disorder characterized by deregulated programmed cell death" refers to a disorder, disease or condition which is characterized by a deregulation, e.g., an upregulation or a downregulation, of programmed cell death. Programmed cell death deregulation can lead to deregulation of cellular proliferation and/or cell cycle progression. Examples of disorders characterized by deregulated programmed cell death include

neurodegenerative disorders, e.g., Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, Jakob-Creutzfeldt disease, or AIDS related dementias; ischemic injury, e.g., myocardial infarction, stroke, or reperfusion injury; or proliferative disorders, e.g., cancer.

Isolated proteins of the present invention, preferably NIP2b, NIP2cL, and NIP2cS proteins, have an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8 or are encoded by a nucleotide sequence sufficiently homologous to SEQ ID NO:1, 3, 4, 6, 7, or 9. As used herein, the term "sufficiently homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least 30%, 40%, or 50% homology, preferably 60% homology, more preferably 70%-80%, and even more preferably 90-95% homology across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently homologous. Furthermore, amino acid or nucleotide sequences which share at least 30%, 40%, or 50%, preferably 60%, more preferably 70-80%, or 90-95% homology and share a common functional activity are defined herein as sufficiently homologous.

As used interchangeably herein, an "NIP2b, NIP2cL, and NIP2cS activity", "biological activity of NIP2b, NIP2cL, and NIP2cS" or "functional activity of NIP2b, NIP2cL, and NIP2cS", refers to an activity exerted by a NIP2b, NIP2cL, and NIP2cS protein, polypeptide or nucleic acid molecule on a NIP2b, NIP2cL, and NIP2cS responsive cell or on a NIP2b, NIP2cL, and NIP2cS protein substrate, as determined *in vivo*, or *in vitro*, according to standard techniques. In one embodiment, a NIP2b, NIP2cL, and NIP2cS activity is a direct activity, such as an association with a NIP2b, NIP2cL, and NIP2cS-target molecule. As used herein, a "target molecule" or "binding partner" is a molecule with which a NIP2b, NIP2cL, and NIP2cS protein binds or interacts in nature, such that NIP2b, NIP2cL, and NIP2cS-mediated function is achieved. An NIP2b, NIP2cL, and NIP2cS target molecule can be a non-NIP2b, non-NIP2cL, and non-NIP2cS molecule or a NIP2b, NIP2cL, and NIP2cS protein or polypeptide of the present invention. In an exemplary embodiment, a NIP2b, NIP2cL, and NIP2cS target molecule is a NIP2b, NIP2cL, and NIP2cS ligand. Alternatively, a NIP2b, NIP2cL, and NIP2cS activity is an indirect activity, such as a cellular signaling activity mediated by interaction of the NIP2b, NIP2cL, and NIP2cS protein with a NIP2b, NIP2cL, and NIP2cS ligand.

Accordingly, another embodiment of the invention features isolated NIP2b, NIP2cL, and NIP2cS proteins and polypeptides having a NIP2b, NIP2cL, and NIP2cS activity.

Preferred proteins are NIP2b, NIP2cL, and NIP2cS proteins having at least one transmembrane domain and, preferably, a NIP2b, NIP2cL, and NIP2cS activity. Other preferred proteins are NIP2b, NIP2cL, and NIP2cS proteins having at least one calcium-binding domain and, preferably, a NIP2b, NIP2cL, and NIP2cS activity. Other preferred
5 proteins are NIP2b, NIP2cL, and NIP2cS proteins having at least one "4 transmembrane segment integral membrane protein domain" and, preferably, a NIP2b, NIP2cL, and NIP2cS activity. Additional preferred proteins have at least one transmembrane domain and/or at least one calcium-binding domain, and/or at least one "4 transmembrane segment integral membrane protein domain", and are, preferably, encoded by a nucleic acid molecule having
10 a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9.

The nucleotide sequence of the isolated human NIP2b cDNA and the predicted amino acid sequence of the human NIP2b polypeptide are shown in Figure 1 and in SEQ ID NOs:1 and 2, respectively. A plasmid containing the nucleotide sequence encoding human
15 NIP2b was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on _____ and assigned Accession Number _____. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and
20 is not an admission that a deposit is required under 35 U.S.C. §112.

The human NIP2b gene, which is approximately 3076 nucleotides in length, encodes a protein having a molecular weight of approximately 42.7 kD and which is approximately 371 amino acid residues in length. A 5kb NIP2b transcript is predominantly expressed in the brain, but on longer exposures this transcript can also be detected in prostate and small
25 intestine. An additional 4kb transcript can also be detected in the heart and skeletal muscle on longer exposures. Within the brain, NIP2b is expressed in most regions. The following areas give a particularly strong signal: cortex, amygdala, striatum, hippocampus, substantia nigra, corpus callosum, cerebellum (Purkinje cells), striatum, basal forebrain, lateral eniculate nucleus, and facial nucleus (motor neurons).

30

The nucleotide sequence of the isolated human NIP2cL cDNA and the predicted amino acid sequence of the human NIP2cL polypeptide are shown in Figure 2 and in SEQ ID NOs:4 and 5, respectively. A plasmid containing the nucleotide sequence encoding human NIP2cL was deposited with the American Type Culture Collection (ATCC), 10801
35 University Boulevard, Manassas, VA 20110-2209, on _____ and assigned Accession Number _____. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent

Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

5 The human NIP2cL gene, which is approximately 4235 nucleotides in length, encodes a protein having a molecular weight of approximately 37 kD and which is approximately 322 amino acid residues in length. The NIP2cL transcript is predominantly expressed in the brain, but can also be detected in the prostate, colon and small intestine. On longer exposures, this transcript can also be detected in the heart, placenta, kidney, pancreas, spleen, testes, ovary and skeletal muscle. In addition, numerous other small transcripts can be seen on longer exposures. Within the brain, NIP2cL is expressed in the following
10 regions: cortex, amygdala, cerebellum (granule cells), hippocampus (dentate gyrus and hippocampal pyramidal cells), striatum, thalamus, locus coeruleus, lateral geniculate nucleus, and facial nucleus (motor neurons).

15 The nucleotide sequence of the isolated human NIP2cS cDNA and the predicted amino acid sequence of the human NIP2cS polypeptide are shown in Figure 3 and in SEQ ID NOs:7 and 8, respectively. A plasmid containing the nucleotide sequence encoding human NIP2cS was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on _____ and assigned Accession Number _____. This deposit will be maintained under the terms of the Budapest Treaty on
20 the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

25 The human NIP2cS gene, which is approximately 2966 nucleotides in length, encodes a protein having a molecular weight of approximately 14.5 kD and which is approximately 126 amino acid residues in length. The NIP2cS transcript is predominantly expressed in the heart, skeletal muscle, and brain.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode NIP2b, NIP2cL, and NIP2cS proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify NIP2b, NIP2cL, and NIP2cS-encoding nucleic acid molecules (e.g., NIP2b, NIP2cL, and NIP2cS mRNA) and fragments for use as PCR primers for the amplification or mutation of NIP2b, NIP2cL, and NIP2cS nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term "isolated nucleic acid molecule" includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated" includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NIP2b, NIP2cL, and NIP2cS nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, as a hybridization probe, NIP2b, NIP2cL, and NIP2cS nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with

ATCC as Accession Number _____ can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____.

- 5 A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NIP2b, NIP2cL, and NIP2cS nucleotide
- 10 sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

- In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1. The sequence of SEQ ID NO:1 corresponds to the human NIP2b cDNA. This cDNA comprises sequences encoding the
- 15 human NIP2b protein (i.e., "the coding region", from nucleotides 370-1482), as well as 5' untranslated sequences (nucleotides 1-369) and 3' untranslated sequences (nucleotides 1483-3076). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:1 (e.g., nucleotides 370-1482, corresponding to SEQ ID NO:3).

- In a preferred embodiment, an isolated nucleic acid molecule of the invention
- 20 comprises the nucleotide sequence shown in SEQ ID NO:4. The sequence of SEQ ID NO:4 corresponds to the human NIP2cL cDNA. This cDNA comprises sequences encoding the human NIP2cL protein (i.e., "the coding region", from nucleotides 23-988), as well as 5' untranslated sequences (nucleotides 1-22) and 3' untranslated sequences (nucleotides 989-4235). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ
- 25 ID NO:4 (e.g., nucleotides 23-988, corresponding to SEQ ID NO:6).

- In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:7. The sequence of SEQ ID NO:7 corresponds to the human NIP2cS cDNA. This cDNA comprises sequences encoding the human NIP2cS protein (i.e., "the coding region", from nucleotides 56-433), as well as 5'
- 30 untranslated sequences (nucleotides 1-55) and 3' untranslated sequences (nucleotides 434-2966). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:7 (e.g., nucleotides 56-433, corresponding to SEQ ID NO:9).

- In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown
- 35 in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA

insert of the plasmid deposited with ATCC as Accession Number _____, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, such that it can hybridize to the nucleotide sequence shown in
5 SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 59%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the
10 nucleotide sequence shown in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the entire length of the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion of any of these nucleotide sequences.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the
15 DNA insert of the plasmid deposited with ATCC as Accession Number _____, for example, a fragment which can be used as a probe or primer or a fragment encoding a portion of a NIP2b, NIP2cL, and NIP2cS protein, e.g., a biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein. The nucleotide sequence determined from the cloning of the NIP2b, NIP2cL, and NIP2cS gene allows for the generation of probes and primers designed for use
20 in identifying and/or cloning other NIP2b, NIP2cL, and NIP2cS family members, as well as NIP2b, NIP2cL, and NIP2cS homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75
25 consecutive nucleotides of a sense sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, of an anti-sense sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or of a naturally occurring allelic variant or mutant of SEQ ID NO:1, 3, 4, 6, 7, or 9,
30 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is greater than 300-350, 350-400, 400-450, 461, 462-500, 535, 536-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, or more nucleotides in length and hybridizes under
35 stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____.

Seq. ID NO: 1, 3, 4, 6, 7, 9

Probes based on the NIP2b, NIP2cL, and NIP2cS nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-

5 factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a NIP2b, NIP2cL, and NIP2cS protein, such as by measuring a level of a NIP2b, NIP2cL, and NIP2cS-encoding nucleic acid in a sample of cells from a subject e.g., detecting NIP2b, NIP2cL, and NIP2cS mRNA levels or determining whether a genomic NIP2b, NIP2cL, and NIP2cS gene has been mutated or deleted.

10 A nucleic acid fragment encoding a "biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, which encodes a polypeptide having a NIP2b, NIP2cL, and NIP2cS biological activity (the biological activities of the NIP2b,

15 NIP2cL, and NIP2cS proteins are described herein), expressing the encoded portion of the NIP2b, NIP2cL, and NIP2cS protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the NIP2b, NIP2cL, and NIP2cS protein.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, due to degeneracy of the genetic code and thus encode the same NIP2b, NIP2cL, and NIP2cS

20 proteins as those encoded by the nucleotide sequence shown in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In another embodiment, an isolated nucleic acid molecule of the

25 invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:2, 5, or 8.

In addition to the NIP2b, NIP2cL, and NIP2cS nucleotide sequences shown in SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, it will be appreciated by those skilled in

30 the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NIP2b, NIP2cL, and NIP2cS proteins may exist within a population (e.g., the human population). Such genetic polymorphism in the NIP2b, NIP2cL, and NIP2cS genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which include an

35 open reading frame encoding a NIP2b, NIP2cL, and NIP2cS protein, preferably a mammalian NIP2b, NIP2cL, and NIP2cS protein, and can further include non-coding regulatory sequences, and introns.

6642760

Allelic variants of human NIP2b, NIP2cL, and NIP2cS include both functional and non-functional NIP2b, NIP2cL, and NIP2cS proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the human NIP2b, NIP2cL, and NIP2cS protein that maintain the ability to bind a NIP2b, NIP2cL, and NIP2cS ligand and/or
5 modulate programmed cell death. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO:2, 5, or 8 or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein.

Non-functional allelic variants are naturally occurring amino acid sequence variants
10 of the human NIP2b, NIP2cL, and NIP2cS protein that do not have the ability to either bind a NIP2b, NIP2cL, and NIP2cS ligand and/or modulate programmed cell death. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID NO:2, 5, or 8 or a substitution, insertion or deletion in critical residues or critical regions.

The present invention further provides non-human orthologues of the human NIP2b, NIP2cL, and NIP2cS protein. Orthologues of the human NIP2b, NIP2cL, and NIP2cS
15 protein are proteins that are isolated from non-human organisms and possess the same NIP2b, NIP2cL, and NIP2cS ligand binding and/or modulation of programmed cell death capabilities of the human NIP2b, NIP2cL, and NIP2cS protein. Orthologues of the human
20 NIP2b, NIP2cL, and NIP2cS protein can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID NO:2, 5, or 8.

Moreover, nucleic acid molecules encoding other NIP2b, NIP2cL, and NIP2cS family members and, thus, which have a nucleotide sequence which differs from the NIP2b, NIP2cL, and NIP2cS sequences of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence
25 of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ are intended to be within the scope of the invention. For example, another NIP2b, NIP2cL, and NIP2cS cDNA can be identified based on the nucleotide sequence of human NIP2b, NIP2cL, and NIP2cS. Moreover, nucleic acid molecules encoding NIP2b, NIP2cL, and NIP2cS proteins from different species, and which, thus, have a nucleotide sequence which
30 differs from the NIP2b, NIP2cL, and NIP2cS sequences of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ are intended to be within the scope of the invention. For example, a mouse NIP2b, NIP2cL, and NIP2cS cDNA can be identified based on the nucleotide sequence of a human NIP2b, NIP2cL, and NIP2cS.

Nucleic acid molecules corresponding to natural allelic variants and homologues of
35 the NIP2b, NIP2cL, and NIP2cS cDNAs of the invention can be isolated based on their homology to the NIP2b, NIP2cL, and NIP2cS nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard

hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NIP2b, NIP2cL, and NIP2cS cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the NIP2b, NIP2cL, and NIP2cS gene.

5 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____. In other embodiment, the nucleic acid
10 is at least 30, 50, 100, 150, 200, 250, 300, 308, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 950 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about
15 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium
20 chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°C, and even more preferably at 65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic
25 acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In addition to naturally-occurring allelic variants of the NIP2b, NIP2cL, and NIP2cS sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:1, 3, 4,
30 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, thereby leading to changes in the amino acid sequence of the encoded NIP2b, NIP2cL, and NIP2cS proteins, without altering the functional ability of the NIP2b, NIP2cL, and NIP2cS proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence
35 of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of NIP2b, NIP2cL, and NIP2cS (e.g., the sequence of SEQ ID NO:2, 5, or 8) without altering the biological activity, whereas

an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the NIP2b, NIP2cL, and NIP2cS proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, additional amino acid residues that are conserved between the NIP2b, NIP2cL, and NIP2cS proteins of the present invention and other members of the NIP2 family are not likely to be amenable to alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding NIP2b, NIP2cL, and NIP2cS proteins that contain changes in amino acid residues that are not essential for activity. Such NIP2b, NIP2cL, and NIP2cS proteins differ in amino acid sequence from SEQ ID NO:2, 5, or 8, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID NO:2, 5, or 8.

An isolated nucleic acid molecule encoding a NIP2b, NIP2cL, and NIP2cS protein homologous to the protein of SEQ ID NO:2, 5, or 8 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____ by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a NIP2b, NIP2cL, and NIP2cS protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NIP2b, NIP2cL, and NIP2cS coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NIP2b, NIP2cL, and NIP2cS biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited

with ATCC as Accession Number _____, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant NIP2b, NIP2cL, and NIP2cS protein can be assayed for the ability to (1) interact with a non-NIP2b, NIP2cL, and NIP2cS protein molecule, e.g., the adenoviral E1B 19kDa protein or the Bcl-2 protein; (2) activate a NIP2b, NIP2cL, and NIP2cS-dependent signal transduction pathway; or (3) modulate programmed cell death.

In addition to the nucleic acid molecules encoding NIP2b, NIP2cL, and NIP2cS proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire NIP2b, NIP2cL, and NIP2cS coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding NIP2b, NIP2cL, and NIP2cS. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the coding region of human NIP2b, NIP2cL, and NIP2cS corresponds to SEQ ID NO:3, 6, and 9, respectively). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding NIP2b, NIP2cL, and NIP2cS. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding NIP2b, NIP2cL, and NIP2cS disclosed herein (e.g., SEQ ID NO:3, 6, and 9), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NIP2b, NIP2cL, and NIP2cS mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of NIP2b, NIP2cL, and NIP2cS mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NIP2b, NIP2cL, and NIP2cS mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense

nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-
5 2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-
10 isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic
15 acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or
20 genomic DNA encoding a NIP2b, NIP2cL, and NIP2cS protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of
25 administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to
30 peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

35 In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids. Res.* 15:6625-

6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme.

- 5 Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave NIP2b, NIP2cL, and NIP2cS mRNA transcripts to thereby inhibit translation of NIP2b, NIP2cL, and NIP2cS mRNA. A ribozyme having specificity for a NIP2b, NIP2cL, and NIP2cS-encoding nucleic acid can be designed based upon the nucleotide sequence of a NIP2b, NIP2cL, and NIP2cS cDNA disclosed herein (i.e., SEQ ID NO:1, 3, 4, 6, 7, or 9, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number _____). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NIP2b, NIP2cL, and NIP2cS-encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742. Alternatively, NIP2b, NIP2cL, and NIP2cS mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

- 15 Alternatively, NIP2b, NIP2cL, and NIP2cS gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NIP2b, NIP2cL, and NIP2cS (e.g., the NIP2b, NIP2cL, and NIP2cS promoter and/or enhancers) to form triple helical structures that prevent transcription of the NIP2b, NIP2cL, and NIP2cS gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. et al. (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

- 20 In yet another embodiment, the NIP2b, NIP2cL, and NIP2cS nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. et al. (1996) *Bioorganic & Medicinal Chemistry* 4 (1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis

protocols as described in Hyrup B. et al. (1996) *supra*; Perry-O'Keefe et al. *Proc. Natl. Acad. Sci.* 93: 14670-675.

PNAs of NIP2b, NIP2cL, and NIP2cS nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or
5 antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of NIP2b, NIP2cL, and NIP2cS nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as 'artificial restriction
10 enzymes' when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup B. (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. et al. (1996) *supra*; Perry-O'Keefe *supra*).

In another embodiment, PNAs of NIP2b, NIP2cL, and NIP2cS can be modified, (e.g., to enhance their stability or cellular uptake), by attaching lipophilic or other helper
15 groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NIP2b, NIP2cL, and NIP2cS nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition
20 enzymes, (e.g., RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) *supra*). The synthesis
of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) *supra* and Finn P.J. et al. (1996) *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be
25 synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. et al. (1989) *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise
manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. et al. (1996) *supra*). Alternatively, chimeric molecules can be synthesized with a 5'
30 DNA segment and a 3' PNA segment (Peterser, K.H. et al. (1975) *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport
35 across the cell membrane (see, e.g., Letsinger et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered
cleavage agents (See, e.g., Krol et al. (1988) *Bio-Techniques* 6:958-976) or intercalating

agents. (See, e.g., Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

5 II. Isolated NIP2b, NIP2cL, and NIP2cS Proteins and Anti-NIP2b, Anti-NIP2cL, and Anti-NIP2cS Antibodies

One aspect of the invention pertains to isolated NIP2b, NIP2cL, and NIP2cS proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-NIP2b, anti-NIP2cL, and anti-NIP2cS antibodies. In
10 one embodiment, native NIP2b, NIP2cL, and NIP2cS proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NIP2b, NIP2cL, and NIP2cS proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NIP2b, NIP2cL, and NIP2cS protein or polypeptide can be synthesized chemically using standard peptide
15 synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NIP2b, NIP2cL, and NIP2cS protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language
20 "substantially free of cellular material" includes preparations of NIP2b, NIP2cL, and NIP2cS protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NIP2b, NIP2cL, and NIP2cS protein having less than about 30% (by dry weight) of non-NIP2b, NIP2cL, and
25 NIP2cS protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NIP2b, NIP2cL, and NIP2cS protein, still more preferably less than about 10% of non-NIP2b, NIP2cL, and NIP2cS protein, and most preferably less than about 5% non-NIP2b, NIP2cL, and NIP2cS protein. When the NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof is recombinantly produced, it is also preferably
30 substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NIP2b, NIP2cL, and NIP2cS protein in which the protein is separated from
35 chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NIP2b, NIP2cL, and NIP2cS protein having less than about 30% (by dry weight) of chemical precursors or non-NIP2b, NIP2cL, and NIP2cS

chemicals, more preferably less than about 20% chemical precursors or non-NIP2b, NIP2cL, and NIP2cS chemicals, still more preferably less than about 10% chemical precursors or non-NIP2b, NIP2cL, and NIP2cS chemicals, and most preferably less than about 5% chemical precursors or non-NIP2b, NIP2cL, and NIP2cS chemicals.

- 5 As used herein, a "biologically active portion" of a NIP2b, NIP2cL, and NIP2cS protein includes a fragment of a NIP2b, NIP2cL, and NIP2cS protein which participates in an interaction between a NIP2b, NIP2cL, and NIP2cS molecule and a non-NIP2b, NIP2cL, and NIP2cS molecule. Biologically active portions of a NIP2b, NIP2cL, and NIP2cS protein include peptides comprising amino acid sequences sufficiently homologous to or
10 derived from the amino acid sequence of the NIP2b, NIP2cL, and NIP2cS protein, e.g., the amino acid sequence shown in SEQ ID NO:2, 5, or 8, which include less amino acids than the full length NIP2b, NIP2cL, and NIP2cS proteins, and exhibit at least one activity of a NIP2b, NIP2cL, and NIP2cS protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the NIP2b, NIP2cL, and NIP2cS protein, e.g.,
15 modulating cellular programmed cell death. A biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein can be a polypeptide which is, for example, 10, 25, 50, 100, 200 or more amino acids in length. Biologically active portions of a NIP2b, NIP2cL, and NIP2cS protein can be used as targets for developing agents which modulate a NIP2b, NIP2cL, and NIP2cS mediated activity, e.g., programmed cell death.
- 20 In one embodiment, a biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein comprises at least one transmembrane domain, and/or at least one calcium-binding domain, and/or at least one "4 transmembrane segment integral membrane protein domain" domain. It is to be understood that a preferred biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein of the present invention may contain at least one of the above-
25 identified structural domains. A more preferred biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein may contain at least two of the above-identified structural domains. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NIP2b, NIP2cL, and NIP2cS protein.
- 30 In a preferred embodiment, the NIP2b, NIP2cL, and NIP2cS protein has an amino acid sequence shown in SEQ ID NO:2, 5, or 8. In other embodiments, the NIP2b, NIP2cL, and NIP2cS protein is substantially homologous to SEQ ID NO:2, 5, or 8, and retains the functional activity of the protein of SEQ ID NO:2, 5, or 8, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I
35 above. Accordingly, in another embodiment, the NIP2b, NIP2cL, and NIP2cS protein is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID NO:2, 5, or 8.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (e.g., when aligning a second sequence to the NIP2b, NIP2cL, and NIP2cS amino acid sequence of SEQ ID NO:2, 5, or 8 having 177 amino acid residues, at least 80, preferably at least 100, more preferably at least 120, even more preferably at least 140, and even more preferably at least 150, 160 or 170 amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program,

score = 100, wordlength = 12 to obtain nucleotide sequences homologous to NIP2b, NIP2cL, and NIP2cS nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to NIP2b, NIP2cL, and NIP2cS protein molecules of the invention.

- 5 To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

- The invention also provides NIP2b, NIP2cL, and NIP2cS chimeric or fusion
10 proteins. As used herein, a NIP2b, NIP2cL, and NIP2cS "chimeric protein" or "fusion protein" comprises a NIP2b, NIP2cL, and NIP2cS polypeptide operatively linked to a non-NIP2b, NIP2cL, and NIP2cS polypeptide. An "NIP2b, NIP2cL, and NIP2cS polypeptide" refers to a polypeptide having an amino acid sequence corresponding to NIP2b, NIP2cL, and NIP2cS, whereas a "non-NIP2b, NIP2cL, and NIP2cS polypeptide" refers to a polypeptide
15 having an amino acid sequence corresponding to a protein which is not substantially homologous to the NIP2b, NIP2cL, and NIP2cS protein, e.g., a protein which is different from the NIP2b, NIP2cL, and NIP2cS protein and which is derived from the same or a different organism. Within a NIP2b, NIP2cL, and NIP2cS fusion protein the NIP2b, NIP2cL, and NIP2cS polypeptide can correspond to all or a portion of a NIP2b, NIP2cL, and NIP2cS protein. In a preferred embodiment, a NIP2b, NIP2cL, and NIP2cS fusion
20 protein comprises at least one biologically active portion of a NIP2b, NIP2cL, and NIP2cS protein. In another preferred embodiment, a NIP2b, NIP2cL, and NIP2cS fusion protein comprises at least two biologically active portions of a NIP2b, NIP2cL, and NIP2cS protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the
25 NIP2b, NIP2cL, and NIP2cS polypeptide and the non-NIP2b, NIP2cL, and NIP2cS polypeptide are fused in-frame to each other. The non-NIP2b, NIP2cL, and NIP2cS polypeptide can be fused to the N-terminus or C-terminus of the NIP2b, NIP2cL, and NIP2cS polypeptide.

- For example, in one embodiment, the fusion protein is a GST-NIP2b, NIP2cL, and
30 NIP2cS fusion protein in which the NIP2b, NIP2cL, and NIP2cS sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant NIP2b, NIP2cL, and NIP2cS.

- In another embodiment, the fusion protein is a NIP2b, NIP2cL, and NIP2cS protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g.,
35 mammalian host cells), expression and/or secretion of NIP2b, NIP2cL, and NIP2cS can be increased through use of a heterologous signal sequence.

The NIP2b, NIP2cL, and NIP2cS fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The

NIP2b, NIP2cL, and NIP2cS fusion proteins can be used to affect the bioavailability of a NIP2b, NIP2cL, and NIP2cS substrate. Use of NIP2b, NIP2cL, and NIP2cS fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a NIP2b, NIP2cL, and NIP2cS protein; (ii) mis-regulation of the NIP2b, NIP2cL, and NIP2cS gene; and (iii) aberrant post-translational modification of a NIP2b, NIP2cL, and NIP2cS protein.

Moreover, the NIP2b, NIP2cL, and NIP2cS-fusion proteins of the invention can be used as immunogens to produce anti-NIP2b, NIP2cL, and NIP2cS antibodies in a subject, to purify NIP2b, NIP2cL, and NIP2cS ligands and in screening assays to identify molecules which inhibit the interaction of NIP2b, NIP2cL, and NIP2cS with a NIP2b, NIP2cL, and NIP2cS substrate.

Preferably, a NIP2b, NIP2cL, and NIP2cS chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An NIP2b, NIP2cL, and NIP2cS-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NIP2b, NIP2cL, and NIP2cS protein.

The present invention also pertains to variants of the NIP2b, NIP2cL, and NIP2cS proteins which function as either NIP2b, NIP2cL, and NIP2cS agonists (mimetics) or as NIP2b, NIP2cL, and NIP2cS antagonists. Variants of the NIP2b, NIP2cL, and NIP2cS proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of a NIP2b, NIP2cL, and NIP2cS protein. An agonist of the NIP2b, NIP2cL, and NIP2cS proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a NIP2b, NIP2cL, and NIP2cS protein. An antagonist of a NIP2b, NIP2cL, and NIP2cS protein can inhibit one or more of the activities of the naturally occurring form of the NIP2b, NIP2cL, and NIP2cS protein by, for example, competitively modulating a NIP2b, NIP2cL, and NIP2cS-mediated activity of a NIP2b, NIP2cL, and NIP2cS protein. Thus, specific biological effects can be elicited by treatment with a variant

of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NIP2b, NIP2cL, and NIP2cS protein.

- 5 In one embodiment, variants of a NIP2b, NIP2cL, and NIP2cS protein which function as either NIP2b, NIP2cL, and NIP2cS agonists (mimetics) or as NIP2b, NIP2cL, and NIP2cS antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a NIP2b, NIP2cL, and NIP2cS protein for NIP2b, NIP2cL, and NIP2cS protein agonist or antagonist activity. In one embodiment, a variegated library of
- 10 NIP2b, NIP2cL, and NIP2cS variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NIP2b, NIP2cL, and NIP2cS variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NIP2b, NIP2cL, and NIP2cS sequences is expressible as individual
- 15 polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NIP2b, NIP2cL, and NIP2cS sequences therein. There are a variety of methods which can be used to produce libraries of potential NIP2b, NIP2cL, and NIP2cS variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene
- 20 then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NIP2b, NIP2cL, and NIP2cS sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike
- 25 et al. (1983) *Nucleic Acid Res.* 11:477.

- In addition, libraries of fragments of a NIP2b, NIP2cL, and NIP2cS protein coding sequence can be used to generate a variegated population of NIP2b, NIP2cL, and NIP2cS fragments for screening and subsequent selection of variants of a NIP2b, NIP2cL, and NIP2cS protein. In one embodiment, a library of coding sequence fragments can be
- 30 generated by treating a double stranded PCR fragment of a NIP2b, NIP2cL, and NIP2cS coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease,
- 35 and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the NIP2b, NIP2cL, and NIP2cS protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NIP2b, NIP2cL, and NIP2cS proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NIP2b, NIP2cL, and NIP2cS variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

In one embodiment, cell based assays can be exploited to analyze a variegated NIP2b, NIP2cL, and NIP2cS library. For example, a library of expression vectors can be transfected into a cell line which ordinarily responds to a particular ligand in a NIP2b, NIP2cL, and NIP2cS-dependent manner. The transfected cells are then contacted with the ligand and the effect of expression of the mutant on signaling by the ligand can be detected, e.g., by measuring cell survival or the activity of a NIP2b, NIP2cL, and NIP2cS-regulated transcription factor. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the ligand, and the individual clones further characterized.

An isolated NIP2b, NIP2cL, and NIP2cS protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind NIP2b, NIP2cL, and NIP2cS using standard techniques for polyclonal and monoclonal antibody preparation. A full-length NIP2b, NIP2cL, and NIP2cS protein can be used or, alternatively, the invention provides antigenic peptide fragments of NIP2b, NIP2cL, and NIP2cS for use as immunogens. The antigenic peptide of NIP2b, NIP2cL, and NIP2cS comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2, 5, or 8 and encompasses an epitope of NIP2b, NIP2cL, and NIP2cS such that an antibody raised against the peptide forms a specific immune complex with NIP2b, NIP2cL, and NIP2cS. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of NIP2b, NIP2cL, and NIP2cS that are located on the surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity (see, for example, Figures 4, 5, and 6).

A NIP2b, NIP2cL, and NIP2cS immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed NIP2b, NIP2cL, and NIP2cS protein or a chemically synthesized NIP2b, NIP2cL, and NIP2cS polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic NIP2b, NIP2cL, and NIP2cS preparation induces a polyclonal anti-NIP2b, NIP2cL, and NIP2cS antibody response.

Accordingly, another aspect of the invention pertains to anti-NIP2b, NIP2cL, and NIP2cS antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as NIP2b, NIP2cL, and NIP2cS. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind NIP2b, NIP2cL, and NIP2cS. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of NIP2b, NIP2cL, and NIP2cS. A monoclonal antibody composition thus typically displays a single binding affinity for a particular NIP2b, NIP2cL, and NIP2cS protein with which it immunoreacts.

Polyclonal anti-NIP2b, NIP2cL, and NIP2cS antibodies can be prepared as described above by immunizing a suitable subject with a NIP2b, NIP2cL, and NIP2cS immunogen. The anti-NIP2b, NIP2cL, and NIP2cS antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized NIP2b, NIP2cL, and NIP2cS. If desired, the antibody molecules directed against NIP2b, NIP2cL, and NIP2cS can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-NIP2b, NIP2cL, and NIP2cS antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown et al. (1981) *J. Immunol.* 127:539-46; Brown et al. (1980) *J. Biol. Chem.* 255:4980-83; Yeh et al. (1976) *Proc. Natl. Acad. Sci. USA* 76:2927-31; and Yeh et al. (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody

hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter et al. (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to

- 5 lymphocytes (typically splenocytes) from a mammal immunized with a NIP2b, NIP2cL, and NIP2cS immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds NIP2b, NIP2cL, and NIP2cS.

- Any of the many well known protocols used for fusing lymphocytes and
- 10 immortalized cell lines can be applied for the purpose of generating an anti-NIP2b, NIP2cL, and NIP2cS monoclonal antibody (see, e.g., G. Galfre et al. (1977) *Nature* 266:55052; Gefter et al. *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful.
- 15 Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine,
- 20 aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then
- 25 selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind NIP2b, NIP2cL, and NIP2cS, e.g., using a standard ELISA assay.

- 30 Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-NIP2b, NIP2cL, and NIP2cS antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with NIP2b, NIP2cL, and NIP2cS to thereby isolate immunoglobulin library members that bind NIP2b, NIP2cL, and NIP2cS. Kits for generating and screening phage display libraries
- 35 are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al.

- U.S. Patent No. 5,223,409; Kang et al. PCT International Publication No. WO 92/18619; Dower et al. PCT International Publication No. WO 91/17271; Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO 93/01288; McCafferty et al. PCT International Publication No. WO 92/01047; Garrard et al. PCT International Publication No. WO 92/09690; Ladner et al. PCT International Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J* 12:725-734; Hawkins et al. (1992) *J. Mol. Biol.* 226:889-896; Clarkson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty et al. *Nature* (1990) 348:552-554.

- Additionally, recombinant anti-NIP2b, NIP2cL, and NIP2cS antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-1043; Liu et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi et al. (1986) *BioTechniques* 4:214; Winter U.S. Patent 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeven et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060.

- An anti-NIP2b, NIP2cL, and NIP2cS antibody (e.g., monoclonal antibody) can be used to isolate NIP2b, NIP2cL, and NIP2cS by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NIP2b, NIP2cL, and NIP2cS antibody can facilitate the purification of natural NIP2b, NIP2cL, and NIP2cS from cells and of recombinantly produced NIP2b, NIP2cL, and NIP2cS expressed in host cells. Moreover, an anti-NIP2b, NIP2cL, and NIP2cS antibody can be used to detect NIP2b, NIP2cL, and NIP2cS protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NIP2b, NIP2cL, and NIP2cS protein. Anti-

5 NIP2b, NIP2cL, and NIP2cS antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

15 III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NIP2b, NIP2cL, and NIP2cS protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

35 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the

nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NIP2b, NIP2cL, and NIP2cS proteins, mutant forms of NIP2b, NIP2cL, and NIP2cS proteins, fusion proteins, and the like).

The recombinant expression vectors of the invention can be designed for expression of NIP2b, NIP2cL, and NIP2cS proteins in prokaryotic or eukaryotic cells. For example, NIP2b, NIP2cL, and NIP2cS proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5

(Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in NIP2b, NIP2cL, and NIP2cS activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate
5 antibodies specific for NIP2b, NIP2cL, and NIP2cS proteins, for example. In a preferred embodiment, a NIP2b, NIP2cL, and NIP2cS fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).

10 Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET
15 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the
20 protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et
25 al., (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NIP2b, NIP2cL, and NIP2cS expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include
30 pYepSec1 (Baldari, et al., (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (InVitrogen Corp, San Diego, CA).

Alternatively, NIP2b, NIP2cL, and NIP2cS proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of
35 proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian

expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.*

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to NIP2b, NIP2cL, and NIP2cS mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule of the invention is introduced, e.g., a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule within a recombinant expression vector or a NIP2b, NIP2cL, and NIP2cS nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a NIP2b, NIP2cL, and NIP2cS protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a NIP2b, NIP2cL, and NIP2cS protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a NIP2b, NIP2cL, and NIP2cS protein. Accordingly, the invention further provides methods for producing a NIP2b, NIP2cL, and NIP2cS protein using the host cells of the invention. In one embodiment, the method comprises culturing

the host cell of invention (into which a recombinant expression vector encoding a NIP2b, NIP2cL, and NIP2cS protein has been introduced) in a suitable medium such that a NIP2b, NIP2cL, and NIP2cS protein is produced. In another embodiment, the method further comprises isolating a NIP2b, NIP2cL, and NIP2cS protein from the medium or the host cell.

5 The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NIP2b, NIP2cL, and NIP2cS-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NIP2b, NIP2cL, and NIP2cS sequences have been introduced into their
10 genome or homologous recombinant animals in which endogenous NIP2b, NIP2cL, and NIP2cS sequences have been altered. Such animals are useful for studying the function and/or activity of a NIP2b, NIP2cL, and NIP2cS and for identifying and/or evaluating modulators of NIP2b, NIP2cL, and NIP2cS activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or
15 mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product
20 in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NIP2b, NIP2cL, and NIP2cS gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to
25 development of the animal.

A transgenic animal of the invention can be created by introducing a NIP2b, NIP2cL, and NIP2cS-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The NIP2b, NIP2cL, and NIP2cS cDNA sequence of SEQ ID NO:1,
30 4, or 7 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human NIP2b, NIP2cL, and NIP2cS gene, such as a mouse or rat NIP2b, NIP2cL, and NIP2cS gene, can be used as a transgene. Alternatively, a NIP2b, NIP2cL, and NIP2cS gene homologue, such as another NIP2 family member, can be isolated based on hybridization to the NIP2b, NIP2cL, and NIP2cS
35 cDNA sequences of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the DNA insert of the plasmid deposited with ATCC as Accession Number _____ (described further in subsection I above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-

specific regulatory sequence(s) can be operably linked to a NIP2b, NIP2cL, and NIP2cS transgene to direct expression of a NIP2b, NIP2cL, and NIP2cS protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al. and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of a NIP2b, NIP2cL, and NIP2cS transgene in its genome and/or expression of NIP2b, NIP2cL, and NIP2cS mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a NIP2b, NIP2cL, and NIP2cS protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NIP2b, NIP2cL, and NIP2cS gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NIP2b, NIP2cL, and NIP2cS gene. The NIP2b, NIP2cL, and NIP2cS gene can be a human gene (e.g., the cDNA of SEQ ID NO:3, 6, or 9), but more preferably, is a non-human homologue of a human NIP2b, NIP2cL, and NIP2cS gene (e.g., a cDNA isolated by stringent hybridization with the nucleotide sequence of SEQ ID NO:1, 4, or 7). For example, a mouse NIP2b, NIP2cL, and NIP2cS gene can be used to construct a homologous recombination nucleic acid molecule, e.g., a vector, suitable for altering an endogenous NIP2b, NIP2cL, and NIP2cS gene in the mouse genome. In a preferred embodiment, the homologous recombination nucleic acid molecule is designed such that, upon homologous recombination, the endogenous NIP2b, NIP2cL, and NIP2cS gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the homologous recombination nucleic acid molecule can be designed such that, upon homologous recombination, the endogenous NIP2b, NIP2cL, and NIP2cS gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NIP2b, NIP2cL, and NIP2cS protein). In the homologous recombination nucleic acid molecule, the altered portion of the NIP2b, NIP2cL, and NIP2cS gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the NIP2b, NIP2cL, and NIP2cS gene to allow for homologous recombination to occur between the exogenous NIP2b, NIP2cL, and NIP2cS gene carried by the homologous recombination nucleic acid molecule and an endogenous NIP2b, NIP2cL, and NIP2cS gene in a cell, e.g., an embryonic stem cell. The additional flanking NIP2b, NIP2cL, and NIP2cS nucleic acid sequence is of sufficient length for

successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the homologous recombination nucleic acid molecule (see, e.g., Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The homologous recombination nucleic acid molecule is introduced into a cell, e.g., an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NIP2b, NIP2cL, and NIP2cS gene has homologously recombined with the endogenous NIP2b, NIP2cL, and NIP2cS gene are selected (see e.g., Li, E. et al. (1992) *Cell* 69:915). The selected cells can then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination nucleic acid molecules, e.g., vectors, or homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.

In another embodiment, transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne

of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

IV. Pharmaceutical Compositions

5 The NIP2b, NIP2cL, and NIP2cS nucleic acid molecules, fragments of NIP2b, NIP2cL, and NIP2cS proteins, and anti-NIP2b, anti-NIP2cL, and anti-NIP2cS antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically
10 comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible
15 with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include
20 parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating
25 agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

30 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be
35 sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol,

propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various
5 antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum
10 monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a fragment of a NIP2b, NIP2cL, and NIP2cS protein or an anti-NIP2b, anti-NIP2cL, and anti-NIP2cS antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

15 Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient
20 from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. oral compositions can also be prepared
25 using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth
30 or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an
35 aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be

permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are

5 formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect

10 the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be

15 obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

20 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical

25 carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard

30 pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side

35 effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic). As described herein, a NIP2b, NIP2cL, and NIP2cS protein of the invention has one or more of the following activities: (1) it interacts with a non-NIP2b, NIP2cL, and NIP2cS protein molecule, e.g., the adenoviral E1B 19kDa protein or the Bcl-2 protein; (2) it activates a NIP2b, NIP2cL, and NIP2cS-dependent signal transduction pathway; and (3) it modulates programmed cell death, and, thus, can be used to, for example, (1) modulate the interaction with a non-NIP2b, NIP2cL, and NIP2cS protein molecule; (2) to activate a NIP2b, NIP2cL, and NIP2cS-dependent signal transduction pathway; and (3) to modulate programmed cell death.

The isolated nucleic acid molecules of the invention can be used, for example, to express NIP2b, NIP2cL, and NIP2cS protein (e.g., via a recombinant expression vector in a

host cell in gene therapy applications), to detect NIP2b, NIP2cL, and NIP2cS mRNA (e.g., in a biological sample) or a genetic alteration in a NIP2b, NIP2cL, and NIP2cS gene, and to modulate NIP2b, NIP2cL, and NIP2cS activity, as described further below. The NIP2b, NIP2cL, and NIP2cS proteins can be used to treat disorders characterized by insufficient or excessive production of a NIP2b, NIP2cL, and NIP2cS substrate or production of NIP2b, NIP2cL, and NIP2cS inhibitors. In addition, the NIP2b, NIP2cL, and NIP2cS proteins can be used to screen for naturally occurring NIP2b, NIP2cL, and NIP2cS substrates, to screen for drugs or compounds which modulate NIP2b, NIP2cL, and NIP2cS activity, as well as to treat disorders characterized by insufficient or excessive production of NIP2b, NIP2cL, and NIP2cS protein or production of NIP2b, NIP2cL, and NIP2cS protein forms which have decreased or aberrant activity compared to NIP2b, NIP2cL, and NIP2cS wild type protein (e.g., disorders associated with programmed cell death). Moreover, the anti-NIP2b, NIP2cL, and NIP2cS antibodies of the invention can be used to detect and isolate NIP2b, NIP2cL, and NIP2cS proteins, regulate the bioavailability of NIP2b, NIP2cL, and NIP2cS proteins, and modulate NIP2b, NIP2cL, and NIP2cS activity.

A. Screening Assays:

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to NIP2b, NIP2cL, and NIP2cS proteins, have a stimulatory or inhibitory effect on, for example, NIP2b, NIP2cL, and NIP2cS expression or NIP2b, NIP2cL, and NIP2cS activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of NIP2b, NIP2cL, and NIP2cS substrate.

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a NIP2b, NIP2cL, and NIP2cS protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a NIP2b, NIP2cL, and NIP2cS protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate NIP2b, NIP2cL, and NIP2cS activity is determined. Determining the ability of the test compound to modulate NIP2b, NIP2cL, and NIP2cS activity can be accomplished by monitoring, for example, the survival of a cell which expresses NIP2b, NIP2cL, and NIP2cS or the activity of a NIP2b, NIP2cL, and NIP2cS-regulated transcription factor. The cell, for example, can be of mammalian origin, e.g., a neuronal cell.

The ability of the test compound to modulate NIP2b, NIP2cL, and NIP2cS binding to a substrate or to bind to NIP2b, NIP2cL, and NIP2cS can also be determined. Determining the ability of the test compound to modulate NIP2b, NIP2cL, and NIP2cS binding to a substrate can be accomplished, for example, by coupling the NIP2b, NIP2cL, and NIP2cS substrate with a radioisotope or enzymatic label such that binding of the NIP2b, NIP2cL, and NIP2cS substrate to NIP2b, NIP2cL, and NIP2cS can be determined by detecting the labeled NIP2b, NIP2cL, and NIP2cS substrate in a complex. Determining the ability of the test compound to bind NIP2b, NIP2cL, and NIP2cS can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to NIP2b, NIP2cL, and NIP2cS can be determined by detecting the labeled NIP2b, NIP2cL, and NIP2cS compound in a complex. For example, compounds (e.g., NIP2b, NIP2cL, and NIP2cS substrates) can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

It is also within the scope of this invention to determine the ability of a compound (e.g., a NIP2b, NIP2cL, and NIP2cS substrate) to interact with NIP2b, NIP2cL, and NIP2cS without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with NIP2b, NIP2cL, and NIP2cS without the labeling of either the compound or the NIP2b, NIP2cL, and NIP2cS. McConnell, H. M. et al. (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (e.g., Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and NIP2b, NIP2cL, and NIP2cS.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a NIP2b, NIP2cL, and NIP2cS target molecule (e.g., a NIP2b, NIP2cL, and NIP2cS substrate) with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NIP2b, NIP2cL, and NIP2cS target molecule. Determining the ability of the test compound to modulate the activity of a NIP2b, NIP2cL, and NIP2cS target molecule can be accomplished, for example, by determining the ability of the NIP2b, NIP2cL, and NIP2cS protein to bind to or interact with the NIP2b, NIP2cL, and NIP2cS target molecule.

Determining the ability of the NIP2b, NIP2cL, and NIP2cS protein or a biologically active fragment thereof, to bind to or interact with a NIP2b, NIP2cL, and NIP2cS target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the NIP2b, NIP2cL, and NIP2cS protein to bind to or interact with a NIP2b, NIP2cL, and NIP2cS target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e., intracellular Ca^{2+} , diacylglycerol, IP_3 , and the like), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a target-regulated cellular response.

In yet another embodiment, an assay of the present invention is a cell-free assay in which a NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof is determined. Preferred biologically active portions of the NIP2b, NIP2cL, and NIP2cS proteins to be used in assays of the present invention include fragments which participate in interactions with non-NIP2b, NIP2cL, and NIP2cS molecules, e.g., fragments with high surface probability scores (see, for example, Figures 4, 5, and 6). Binding of the test compound to the NIP2b, NIP2cL, and

NIP2cS protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof with a known compound which binds NIP2b, NIP2cL, and NIP2cS to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NIP2b, NIP2cL, and NIP2cS protein, wherein determining the ability of the test compound to interact with a NIP2b, NIP2cL, and NIP2cS protein comprises determining the ability of the test compound to preferentially bind to NIP2b, NIP2cL, and NIP2cS or biologically active portion thereof as compared to the known compound.

In another embodiment, the assay is a cell-free assay in which a NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of a NIP2b, NIP2cL, and NIP2cS protein can be accomplished, for example, by determining the ability of the NIP2b, NIP2cL, and NIP2cS protein to bind to a NIP2b, NIP2cL, and NIP2cS target molecule by one of the methods described above for determining direct binding. Determining the ability of the NIP2b, NIP2cL, and NIP2cS protein to bind to a NIP2b, NIP2cL, and NIP2cS target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo et al. (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of a NIP2b, NIP2cL, and NIP2cS protein can be accomplished by determining the ability of the NIP2b, NIP2cL, and NIP2cS protein to further modulate the activity of a downstream effector of a NIP2b, NIP2cL, and NIP2cS target molecule. For example, the activity of the effector molecule on an appropriate target can be determined or the binding of the effector to an appropriate target can be determined as previously described.

In yet another embodiment, the cell-free assay involves contacting a NIP2b, NIP2cL, and NIP2cS protein or biologically active portion thereof with a known compound which binds the NIP2b, NIP2cL, and NIP2cS protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the NIP2b, NIP2cL, and NIP2cS protein, wherein determining the ability of the test compound to interact with the NIP2b, NIP2cL, and NIP2cS protein comprises

determining the ability of the NIP2b, NIP2cL, and NIP2cS protein to preferentially bind to or modulate the activity of a NIP2b, NIP2cL, and NIP2cS target molecule.

The cell-free assays of the present invention are amenable to use of both soluble and/or membrane-bound forms of isolated proteins (e.g., NIP2b, NIP2cL, and NIP2cS proteins or biologically active portions thereof). In the case of cell-free assays in which a membrane-bound form of an isolated protein is used it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the isolated protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either NIP2b, NIP2cL, and NIP2cS or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a NIP2b, NIP2cL, and NIP2cS protein, or interaction of a NIP2b, NIP2cL, and NIP2cS protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ NIP2b, NIP2cL, and NIP2cS fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or NIP2b, NIP2cL, and NIP2cS protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of NIP2b, NIP2cL, and NIP2cS binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a NIP2b, NIP2cL, and NIP2cS protein or a NIP2b, NIP2cL, and NIP2cS target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NIP2b, NIP2cL, and NIP2cS protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using

techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).

Alternatively, antibodies reactive with NIP2b, NIP2cL, and NIP2cS protein or target molecules but which do not interfere with binding of the NIP2b, NIP2cL, and NIP2cS protein to its target molecule can be derivatized to the wells of the plate, and unbound target or NIP2b, NIP2cL, and NIP2cS protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NIP2b, NIP2cL, and NIP2cS protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the NIP2b, NIP2cL, and NIP2cS protein or target molecule.

In another embodiment, modulators of NIP2b, NIP2cL, and NIP2cS expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NIP2b, NIP2cL, and NIP2cS mRNA or protein in the cell is determined. The level of expression of NIP2b, NIP2cL, and NIP2cS mRNA or protein in the presence of the candidate compound is compared to the level of expression of NIP2b, NIP2cL, and NIP2cS mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NIP2b, NIP2cL, and NIP2cS expression based on this comparison. For example, when expression of NIP2b, NIP2cL, and NIP2cS mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NIP2b, NIP2cL, and NIP2cS mRNA or protein expression. Alternatively, when expression of NIP2b, NIP2cL, and NIP2cS mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NIP2b, NIP2cL, and NIP2cS mRNA or protein expression. The level of NIP2b, NIP2cL, and NIP2cS mRNA or protein expression in the cells can be determined by methods described herein for detecting NIP2b, NIP2cL, and NIP2cS mRNA or protein.

In yet another aspect of the invention, the NIP2b, NIP2cL, and NIP2cS proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with NIP2b, NIP2cL, and NIP2cS ("NIP2b-binding proteins", "NIP2cL-binding proteins", and "NIP2cS-binding proteins" or "NIP2b-bp", "NIP2cL-bp", and "NIP2cS-bp") and are involved in NIP2b, NIP2cL, and NIP2cS activity. Such NIP2b, NIP2cL, and NIP2cS-binding proteins are also likely to be involved in the propagation of signals by the NIP2b, NIP2cL, and NIP2cS proteins or NIP2b, NIP2cL, and NIP2cS targets as, for

example, downstream elements of a NIP2b, NIP2cL, and NIP2cS-mediated signaling pathway. Alternatively, such NIP2b, NIP2cL, and NIP2cS-binding proteins are likely to be NIP2b, NIP2cL, and NIP2cS inhibitors.

5 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a NIP2b, NIP2cL, and NIP2cS protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene
10 that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a NIP2b, NIP2cL, and NIP2cS-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the
15 transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the NIP2b, NIP2cL, and NIP2cS protein.

This invention further pertains to novel agents identified by the above-described
20 screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a NIP2b, NIP2cL, and NIP2cS modulating agent, an antisense NIP2b, NIP2cL, and NIP2cS nucleic acid molecule, a NIP2b, NIP2cL, and NIP2cS-specific antibody, or a NIP2b, NIP2cL, and NIP2cS-binding partner) can be used in
25 an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

30

B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a
35 chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

1. Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NIP2b, NIP2cL, and NIP2cS nucleotide sequences, described herein, can be used to map the location of the NIP2b, NIP2cL, and NIP2cS genes on a chromosome. The mapping of the NIP2b, NIP2cL, and NIP2cS sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NIP2b, NIP2cL, and NIP2cS genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NIP2b, NIP2cL, and NIP2cS nucleotide sequences. Computer analysis of the NIP2b, NIP2cL, and NIP2cS sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NIP2b, NIP2cL, and NIP2cS sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. et al. (1983) *Science* 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NIP2b, NIP2cL, and NIP2cS nucleotide sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a NIP2b, NIP2cL, and NIP2cS sequence to its chromosome include *in situ* hybridization (described in Fan, Y. et al. (1990) *Proc. Natl. Acad. Sci. USA*, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical such as colcemid that disrupts the mitotic spindle. The
5 chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of
10 binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al., Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for
15 marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical
20 position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example,
25 Egeland, J. et al. (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NIP2b, NIP2cL, and NIP2cS gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in
30 any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can
35 be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

2. Tissue Typing

The NIP2b, NIP2cL, and NIP2cS sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for
5 identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP
10 (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NIP2b, NIP2cL, and NIP2cS nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends
15 of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can
20 be used to obtain such identification sequences from individuals and from tissue. The NIP2b, NIP2cL, and NIP2cS nucleotide sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per
25 each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:1, 4, or 7 can comfortably provide positive individual identification with a
30 panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3, 6, or 9 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from NIP2b, NIP2cL, and NIP2cS nucleotide sequences
35 described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

3. Use of Partial NIP2b, NIP2cL, and NIP2cS Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1, 4, or 7 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the NIP2b, NIP2cL, and NIP2cS nucleotide sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:1, 4, or 7 having a length of at least 20 bases, preferably at least 30 bases.

The NIP2b, NIP2cL, and NIP2cS nucleotide sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such NIP2b, NIP2cL, and NIP2cS probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, e.g., NIP2b, NIP2cL, and NIP2cS primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).

C. Predictive Medicine:

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining NIP2b, NIP2cL, and NIP2cS protein and/or nucleic acid expression as well as NIP2b, NIP2cL, and NIP2cS activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby

determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NIP2b, NIP2cL, and NIP2cS expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NIP2b, NIP2cL, and NIP2cS protein, nucleic acid expression or activity. For example, mutations in a NIP2b, NIP2cL, and NIP2cS gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NIP2b, NIP2cL, and NIP2cS protein, nucleic acid expression or activity.

Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NIP2b, NIP2cL, and NIP2cS in clinical trials.

These and other agents are described in further detail in the following sections.

1. Diagnostic Assays

An exemplary method for detecting the presence or absence of NIP2b, NIP2cL, and NIP2cS protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NIP2b, NIP2cL, and NIP2cS protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NIP2b, NIP2cL, and NIP2cS protein such that the presence of NIP2b, NIP2cL, and NIP2cS protein or nucleic acid is detected in the biological sample. A preferred agent for detecting NIP2b, NIP2cL, and NIP2cS mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NIP2b, NIP2cL, and NIP2cS mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NIP2b, NIP2cL, and NIP2cS nucleic acid, such as the nucleic acid of SEQ ID NO:1, 3, 4, 6, 7, or 9, or the DNA insert of the plasmid deposited with ATCC as Accession Number _____, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NIP2b, NIP2cL, and NIP2cS mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting NIP2b, NIP2cL, and NIP2cS protein is an antibody capable of binding to NIP2b, NIP2cL, and NIP2cS protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary

antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NIP2b, NIP2cL, and NIP2cS mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NIP2b, NIP2cL, and NIP2cS mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NIP2b, NIP2cL, and NIP2cS protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of NIP2b, NIP2cL, and NIP2cS genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NIP2b, NIP2cL, and NIP2cS protein include introducing into a subject a labeled anti-NIP2b, NIP2cL, and NIP2cS antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a serum sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NIP2b, NIP2cL, and NIP2cS protein, mRNA, or genomic DNA, such that the presence of NIP2b, NIP2cL, and NIP2cS protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NIP2b, NIP2cL, and NIP2cS protein, mRNA or genomic DNA in the control sample with the presence of NIP2b, NIP2cL, and NIP2cS protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NIP2b, NIP2cL, and NIP2cS in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting NIP2b, NIP2cL, and NIP2cS protein or mRNA in a biological sample; means for determining the amount of NIP2b, NIP2cL, and NIP2cS in the sample; and means for comparing the amount of NIP2b, NIP2cL, and NIP2cS in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NIP2b, NIP2cL, and NIP2cS protein or nucleic acid.

2. Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant

NIP2b, NIP2cL, and NIP2cS expression or activity. As used herein, the term "aberrant" includes a NIP2b, NIP2cL, and NIP2cS expression or activity which deviates from the wild type NIP2b, NIP2cL, and NIP2cS expression or activity. Aberrant expression or activity includes increased or decreased expression or activity, as well as expression or activity which does not follow the wild type developmental pattern of expression or the subcellular pattern of expression. For example, aberrant NIP2b, NIP2cL, and NIP2cS expression or activity is intended to include the cases in which a mutation in the NIP2b, NIP2cL, and NIP2cS gene causes the NIP2b, NIP2cL, and NIP2cS gene to be under-expressed or over-expressed and situations in which such mutations result in a non-functional NIP2b, NIP2cL, and NIP2cS protein or a protein which does not function in a wild-type fashion, e.g., a protein which does not interact with a NIP2b, NIP2cL, and NIP2cS ligand or one which interacts with a non-NIP2b, non-NIP2cL, and non-NIP2cS ligand.

The assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with a misregulation in NIP2b, NIP2cL, and NIP2cS protein activity or nucleic acid expression, such as a disorder characterized by deregulated programmed cell death. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disorder associated with a misregulation in NIP2b, NIP2cL, and NIP2cS protein activity or nucleic acid expression, such as a disorder characterized by deregulated programmed cell death. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant NIP2b, NIP2cL, and NIP2cS expression or activity in which a test sample is obtained from a subject and NIP2b, NIP2cL, and NIP2cS protein or nucleic acid (e.g., mRNA or genomic DNA) is detected, wherein the presence of NIP2b, NIP2cL, and NIP2cS protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NIP2b, NIP2cL, and NIP2cS expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NIP2b, NIP2cL, and NIP2cS expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder characterized by deregulated programmed cell death. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NIP2b, NIP2cL, and NIP2cS expression or activity in which a test sample is obtained and NIP2b, NIP2cL, and NIP2cS protein or nucleic acid expression or activity is detected (e.g., wherein the abundance of

NIP2b, NIP2cL, and NIP2cS protein or nucleic acid expression or activity is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NIP2b, NIP2cL, and NIP2cS expression or activity).

The methods of the invention can also be used to detect genetic alterations in a NIP2b, NIP2cL, and NIP2cS gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in NIP2b, NIP2cL, and NIP2cS protein activity or nucleic acid expression, such as a neurodegenerative disorder. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding a NIP2b, NIP2cL, and NIP2cS-protein, or the mis-expression of the NIP2b, NIP2cL, and NIP2cS gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a NIP2b, NIP2cL, and NIP2cS gene; 2) an addition of one or more nucleotides to a NIP2b, NIP2cL, and NIP2cS gene; 3) a substitution of one or more nucleotides of a NIP2b, NIP2cL, and NIP2cS gene; 4) a chromosomal rearrangement of a NIP2b, NIP2cL, and NIP2cS gene; 5) an alteration in the level of a messenger RNA transcript of a NIP2b, NIP2cL, and NIP2cS gene; 6) aberrant modification of a NIP2b, NIP2cL, and NIP2cS gene, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a NIP2b, NIP2cL, and NIP2cS gene; 8) a non-wild type level of a NIP2b, NIP2cL, and NIP2cS-protein; 9) allelic loss of a NIP2b, NIP2cL, and NIP2cS gene; and 10) inappropriate post-translational modification of a NIP2b, NIP2cL, and NIP2cS-protein. As described herein, there are a large number of assays known in the art which can be used for detecting alterations in a NIP2b, NIP2cL, and NIP2cS gene. A preferred biological sample is a tissue or serum sample isolated by conventional means from a subject.

In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the NIP2b, NIP2cL, and NIP2cS-gene (see Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a subject, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a NIP2b, NIP2cL, and NIP2cS gene under conditions such that hybridization and amplification of the NIP2b, NIP2cL, and NIP2cS-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that

PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. et al., (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional
5 amplification system (Kwoh, D.Y. et al., (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177),
Q-Beta Replicase (Lizardi, P.M. et al. (1988) *Bio-Technology* 6:1197), or any other nucleic
acid amplification method, followed by the detection of the amplified molecules using
techniques well known to those of skill in the art. These detection schemes are especially
useful for the detection of nucleic acid molecules if such molecules are present in very low
10 numbers.

In an alternative embodiment, mutations in a NIP2b, NIP2cL, and NIP2cS gene from
a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For
example, sample and control DNA is isolated, amplified (optionally), digested with one or
more restriction endonucleases, and fragment length sizes are determined by gel
15 electrophoresis and compared. Differences in fragment length sizes between sample and
control DNA indicates mutations in the sample DNA. Moreover, the use of sequence
specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the
presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NIP2b, NIP2cL, and NIP2cS can be
20 identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high
density arrays containing hundreds or thousands of oligonucleotides probes (Cronin, M.T. et
al. (1996) *Human Mutation* 7: 244-255; Kozal, M.J. et al. (1996) *Nature Medicine* 2: 753-
759). For example, genetic mutations in NIP2b, NIP2cL, and NIP2cS can be identified in
two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T.
25 *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through long
stretches of DNA in a sample and control to identify base changes between the sequences by
making linear arrays of sequential overlapping probes. This step allows the identification of
point mutations. This step is followed by a second hybridization array that allows the
characterization of specific mutations by using smaller, specialized probe arrays
30 complementary to all variants or mutations detected. Each mutation array is composed of
parallel probe sets, one complementary to the wild-type gene and the other complementary
to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art
can be used to directly sequence the NIP2b, NIP2cL, and NIP2cS gene and detect mutations
35 by comparing the sequence of the sample NIP2b, NIP2cL, and NIP2cS with the
corresponding wild-type (control) sequence. Examples of sequencing reactions include
those based on techniques developed by Maxam and Gilbert ((1977) *Proc. Natl. Acad. Sci.*
USA 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also

contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al. (1996) *Adv. Chromatogr.* 36:127-162; and Griffin et al. (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in the NIP2b, NIP2cL, and NIP2cS gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NIP2b, NIP2cL, and NIP2cS sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al.* (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba et al. (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NIP2b, NIP2cL, and NIP2cS cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a NIP2b, NIP2cL, and NIP2cS sequence, e.g., a wild-type NIP2b, NIP2cL, and NIP2cS sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NIP2b, NIP2cL, and NIP2cS genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (orita *et al.* (1989) *Proc Natl. Acad. Sci USA*: 86:2766, see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet. Anal.*

Tech. Appl. 9:73-79). Single-stranded DNA fragments of sample and control NIP2b, NIP2cL, and NIP2cS nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) *Trends Genet* 7:5).

In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl Acad. Sci USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the

5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NIP2b, NIP2cL, and NIP2cS gene.

Furthermore, any cell type or tissue in which NIP2b, NIP2cL, and NIP2cS is expressed may be utilized in the prognostic assays described herein.

3. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs) on the expression or activity of a NIP2b, NIP2cL, and NIP2cS protein (*e.g.*, the modulation of cellular programmed cell death) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NIP2b, NIP2cL, and NIP2cS gene expression, protein levels, or upregulate NIP2b, NIP2cL, and NIP2cS activity, can be monitored in clinical trials of subjects exhibiting decreased NIP2b, NIP2cL, and NIP2cS gene expression, protein levels, or downregulated NIP2b, NIP2cL, and NIP2cS activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NIP2b, NIP2cL, and NIP2cS gene expression, protein levels, or downregulate NIP2b, NIP2cL, and NIP2cS activity, can be monitored in clinical trials of subjects exhibiting increased NIP2b, NIP2cL, and NIP2cS gene expression, protein levels, or upregulated NIP2b, NIP2cL, and NIP2cS activity. In such clinical trials, the expression or activity of a NIP2b, NIP2cL, and NIP2cS gene, and preferably, other genes that have been implicated in, for example, a NIP2b, NIP2cL, and NIP2cS-associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.

For example, and not by way of limitation, genes, including NIP2b, NIP2cL, and NIP2cS, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) which modulates NIP2b, NIP2cL, and NIP2cS activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on NIP2b, NIP2cL, and NIP2cS-associated disorders (*e.g.*, disorders characterized by deregulated programmed cell death), for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NIP2b, NIP2cL, and NIP2cS and other genes implicated in the NIP2b, NIP2cL, and NIP2cS-associated disorder, respectively. The levels of gene expression (*e.g.*, a gene expression pattern) can be quantified by northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of

activity of NIP2b, NIP2cL, and NIP2cS or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent.

5 In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting
10 the level of expression of a NIP2b, NIP2cL, and NIP2cS protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NIP2b, NIP2cL, and NIP2cS protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NIP2b, NIP2cL, and NIP2cS protein,
15 mRNA, or genomic DNA in the pre-administration sample with the NIP2b, NIP2cL, and NIP2cS protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NIP2b, NIP2cL, and NIP2cS to higher levels than detected, i.e., to increase the
20 effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NIP2b, NIP2cL, and NIP2cS to lower levels than detected, i.e. to decrease the effectiveness of the agent. According to such an embodiment, NIP2b, NIP2cL, and NIP2cS expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic
25 response.

C. Methods of Treatment:

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with
30 aberrant NIP2b, NIP2cL, and NIP2cS expression or activity. With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in
35 clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the

NIP2b, NIP2cL, and NIP2cS molecules of the present invention or NIP2b, NIP2cL, and NIP2cS modulators according to that individual's drug response genotype.

Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

1. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant NIP2b, NIP2cL, and NIP2cS expression or activity, by administering to the subject a NIP2b, NIP2cL, and NIP2cS or an agent which modulates NIP2b, NIP2cL, and NIP2cS expression or at least one NIP2b, NIP2cL, and NIP2cS activity. Subjects at risk for a disease which is caused or contributed to by aberrant NIP2b, NIP2cL, and NIP2cS expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NIP2b, NIP2cL, and NIP2cS aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of NIP2b, NIP2cL, and NIP2cS aberrancy, for example, a NIP2b, NIP2cL, and NIP2cS, NIP2b, NIP2cL, and NIP2cS agonist or NIP2b, NIP2cL, and NIP2cS antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NIP2b, NIP2cL, and NIP2cS expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with a NIP2b, NIP2cL, and NIP2cS or agent that modulates one or more of the activities of NIP2b, NIP2cL, and NIP2cS protein activity associated with the cell. An agent that modulates NIP2b, NIP2cL, and NIP2cS protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of a NIP2b, NIP2cL, and NIP2cS protein (e.g., a NIP2b, NIP2cL, and NIP2cS substrate), a NIP2b, NIP2cL, and NIP2cS antibody, a NIP2b, NIP2cL, and NIP2cS agonist or antagonist, a peptidomimetic of a NIP2b, NIP2cL, and NIP2cS agonist or antagonist, or other small molecule. In one embodiment, the agent stimulates one or more NIP2b, NIP2cL, and NIP2cS activities. Examples of such stimulatory agents include active NIP2b, NIP2cL, and NIP2cS protein and a nucleic acid molecule encoding NIP2b, NIP2cL, and NIP2cS that has been introduced into the cell. In another embodiment, the agent inhibits one or more NIP2b, NIP2cL, and NIP2cS activities. Examples of such inhibitory agents include antisense NIP2b, NIP2cL,

and NIP2cS nucleic acid molecules, anti-NIP2b, NIP2cL, and NIP2cS antibodies, and NIP2b, NIP2cL, and NIP2cS inhibitors. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of

5 treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NIP2b, NIP2cL, and NIP2cS protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) NIP2b, NIP2cL, and NIP2cS expression or activity. In another

10 embodiment, the method involves administering a NIP2b, NIP2cL, and NIP2cS protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NIP2b, NIP2cL, and NIP2cS expression or activity.

Stimulation of NIP2b, NIP2cL, and NIP2cS activity is desirable in situations in which NIP2b, NIP2cL, and NIP2cS is abnormally downregulated and/or in which increased

15 NIP2b, NIP2cL, and NIP2cS activity is likely to have a beneficial effect. For example, stimulation of NIP2b, NIP2cL, and NIP2cS activity is desirable in situations in which a NIP2b, NIP2cL, and NIP2cS is downregulated and/or in which increased NIP2b, NIP2cL, and NIP2cS activity is likely to have a beneficial effect. Likewise, inhibition of NIP2b, NIP2cL, and NIP2cS activity is desirable in situations in which NIP2b, NIP2cL, and NIP2cS

20 is abnormally upregulated and/or in which decreased NIP2b, NIP2cL, and NIP2cS activity is likely to have a beneficial effect.

3. Pharmacogenomics

The NIP2b, NIP2cL, and NIP2cS molecules of the present invention, as well as

25 agents, or modulators which have a stimulatory or inhibitory effect on NIP2b, NIP2cL, and NIP2cS activity (e.g., NIP2b, NIP2cL, and NIP2cS gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) NIP2b, NIP2cL, and NIP2cS-associated disorders (e.g., programmed cell death associated disorders) associated with aberrant NIP2b, NIP2cL, and NIP2cS activity.

30 In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying

35 knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a NIP2b, NIP2cL, and NIP2cS molecule or NIP2b, NIP2cL, and NIP2cS modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a NIP2b, NIP2cL, and NIP2cS molecule or NIP2b, NIP2cL, and NIP2cS modulator.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. et al. (1996) *Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 and Linder, M.W. et al. (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (e.g., a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants.) Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the "candidate gene approach", can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drugs target is known (e.g., a NIP2b, NIP2cL, and NIP2cS protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and

cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Alternatively, a method termed the "gene expression profiling", can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., a NIP2b, NIP2cL, and NIP2cS molecule or NIP2b, NIP2cL, and NIP2cS modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NIP2b, NIP2cL, and NIP2cS molecule or NIP2b, NIP2cL, and NIP2cS modulator, such as a modulator identified by one of the exemplary screening assays described herein.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

EXAMPLES

EXAMPLE 1: IDENTIFICATION AND CHARACTERIZATION OF NIP2b, NIP2cL, and NIP2cS cDNA

In this example, the identification and characterization of the genes encoding human NIP2b, NIP2cL, and NIP2cS is described.

Isolation of the human NIP2b, NIP2cL, and NIP2cS cDNA

The invention is based, at least in part, on the discovery of two human genes
5 encoding two novel proteins, referred to herein as NIP2b and NIP2c (the long isoform:
NIP2cL, and the short isoform: NIP2cS). A clone was originally identified from a monkey
brain library, based on sequence homology to NIP2 proteins. Based on the sequence of this
first clone, primers were designed and used to screen a human brain library (obtained from
Clonetech). Two positive human clones were identified. The entire sequence of the two
10 human clones was determined and found to contain open reading frames termed human
"NIP2b", "NIP2cL", and "NIP2cS."

The nucleotide sequence encoding the human NIP2b protein is shown in Figure 1
and is set forth as SEQ ID NO:1. The full length protein encoded by this nucleic acid
comprises about 371 amino acids and has the amino acid sequence shown in Figure 1 and
15 set forth as SEQ ID NO:2. The coding region (open reading frame) of SEQ ID NO:1 is set
forth as SEQ ID NO:3. Clone NIP2b, comprising the entire coding region of human NIP2b
was deposited with the American Type Culture Collection (ATCC®), 10801 University
Boulevard, Manassas, VA 20110-2209, on _____, and assigned Accession No. ____.

20 The nucleotide sequence encoding the human NIP2cL protein is shown in Figure 2
and is set forth as SEQ ID NO:4. The full length protein encoded by this nucleic acid
comprises about 322 amino acids and has the amino acid sequence shown in Figure 2 and
set forth as SEQ ID NO:5. The coding region (open reading frame) of SEQ ID NO:4 is set
forth as SEQ ID NO:6. Clone NIP2cL, comprising the entire coding region of human
25 NIP2cL was deposited with the American Type Culture Collection (ATCC®), 10801
University Boulevard, Manassas, VA 20110-2209, on _____, and assigned Accession
No. ____.

The nucleotide sequence encoding the human NIP2cS protein is shown in Figure 3
30 and is set forth as SEQ ID NO:7. The full length protein encoded by this nucleic acid
comprises about 126 amino acids and has the amino acid sequence shown in Figure 3 and
set forth as SEQ ID NO:8. The coding region (open reading frame) of SEQ ID NO:7 is set
forth as SEQ ID NO:9. Clone NIP2cS, comprising the entire coding region of human
NIP2cS was deposited with the American Type Culture Collection (ATCC®), 10801
35 University Boulevard, Manassas, VA 20110-2209, on _____, and assigned Accession
No. ____.

Analysis of the Human NIP2b, NIP2cL, and NIP2cS Molecules

A BLASTX 1.4 search, using a score of 100 and a word length of 3 (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the translated nucleotide sequence of human NIP2b revealed that human NIP2b is similar to the Mus Musculus NIP2 protein (Accession Number AF035207) and the human BCL2/adenovirus E1B 19kD-interacting protein 2 (Accession Number U15173) . The human NIP2b protein is 66% identical to the Mus Musculus NIP2 protein (Accession Number AF035207) over translated nucleotides 787 to 1338 and 68% identical to the human BCL2/adenovirus E1B 19kD-interacting protein 2 (Accession Number U15173) over translated nucleotides 787 to 1317.

A BLASTN 1.4.9 search, using a score of 100 and a word length of 12 (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the nucleotide sequence of human NIP2b revealed that NIP2b is similar to the Human mRNA for KIAA0367 (Accession Number AB002365). The NIP2b nucleic acid molecule is 74% identical to the Human mRNA for KIAA0367 (Accession Number AB002365) over nucleotides 793 to 1059.

A BLASTX 1.4 search, using a score of 100 and a word length of 3 (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the translated nucleotide sequence of human NIP2cL revealed that human NIP2cL is similar to the human KIAA0367 (Accession Number AB002365), the human BCL2/adenovirus E1B 19kD-interacting protein 2 (Accession Number U15173), and the Mus Musculus NIP2 protein (Accession Number AF035207). The human NIP2cL protein is 99% identical to the human KIAA0367 (Accession Number AB002365) over translated nucleotides 50 to 520, 64% identical to the human BCL2/adenovirus E1B 19kD-interacting protein 2 (Accession Number U15173) over translated nucleotides 557 to 985, and 64% identical to the Mus Musculus NIP2 protein (Accession Number AF035207) over translated nucleotides 557 to 955.

A BLASTN 1.4.9 search, using a score of 100 and a word length of 12 (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the nucleotide sequence of human NIP2cL revealed that NIP2cL is similar to the Human mRNA for KIAA0367 (Accession Number AB002365). The NIP2cL nucleic acid molecule is 100% identical to the Human mRNA for KIAA0367 (Accession Number AB002365) over nucleotides 960 to 4184, 98% identical over nucleotides 16 to 544, 95% identical over nucleotides 709 to 982, and 99% identical over nucleotides 538 to 716.

A BLASTX 1.4 search, using a score of 100 and a word length of 3 (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the translated nucleotide sequence of human NIP2cS revealed that human NIP2cS is similar to the human KIAA0367 (Accession Number AB002365), and the human BCL2/adenovirus E1B 19kD-interacting protein 2 (Accession Number U15173) . The human NIP2cS protein is 100% identical to the human KIAA0367 (Accession Number AB002365) over translated nucleotides 125 to 403 and 36% identical to

the human BCL2/adenovirus E1B 19kD-interacting protein 2 (Accession Number U15173) over translated nucleotides 134 to 316.

A BLASTN 1.4.9 search, using a score of 100 and a word length of 12 (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the nucleotide sequence of human NIP2cS revealed that

5 NIP2cS is similar to the human cDNA clone IMAGE:1405422 (Accession Number AA843788). The NIP2cS nucleic acid molecule is 100% identical to the human cDNA clone IMAGE:1405422 (Accession Number AA843788) over nucleotides 598 to 1058.

The NIP2b protein was aligned with the human Bcl-2/adenovirus E1B 19kDa-
10 interacting protein 2 (BNIP-2, Accession Number U15173) using the GAP program in the GCG software package (Blossom 62 matrix) and a gap weight of 12 and a length weight of 4. The results showed a 56.051% identity and 67.197% similarity between the two sequences (see Figure 10).

The NIP2b protein was also aligned with the NIP2cL protein using the GAP program
15 in the GCG software package (Blossom 62 matrix) and a gap weight of 12 and a length weight of 4. The results showed a 58.805% identity and 69.182% similarity between the two sequences (see Figure 11).

The NIP2cL protein was also aligned with the human Bcl-2/adenovirus E1B 19kDa-
20 interacting protein 2 (BNIP-2, Accession Number U15173) using the GAP program in the GCG software package (Blossom 62 matrix) and a gap weight of 12 and a length weight of 4. The results showed a 57.705% identity and 67.541% similarity between the two sequences (see Figure 12).

Tissue Distribution of NIP2b, NIP2cL, and NIP2cS mRNA

25 This Example describes the tissue distribution of NIP2b, NIP2cL, and NIP2cS mRNA, as determined by Northern blot hybridization and *in situ* hybridization.

Northern blot hybridizations with the various RNA samples were performed under standard conditions and washed under stringent conditions, i.e., 0.2xSSC at 65°C. The DNA probe was radioactively labeled with ³²P-dCTP using the Prime-It kit (Stratagene, La
30 Jolla, CA) according to the instructions of the supplier. Filters containing human mRNA (MultiTissue Northern I and MultiTissue Northern II from Clontech, Palo Alto, CA) were probed in ExpressHyb hybridization solution (Clontech) and washed at high stringency according to manufacturer's recommendations.

For *in situ* analysis, various tissues obtained from rat and monkey brains were first
35 frozen on dry ice. Ten-micrometer-thick coronal sections of the tissues were postfixed with 4% formaldehyde in DEPC treated 1X phosphate- buffered saline at room temperature for 10 minutes before being rinsed twice in DEPC 1X phosphate-buffered saline and once in 0.1 M triethanolamine-HCl (pH 8.0). Following incubation in 0.25% acetic anhydride-0.1 M

triethanolamine-HCl for 10 minutes, sections were rinsed in DEPC 2X SSC (1X SSC is 0.15M NaCl plus 0.015M sodium citrate). Tissue was then dehydrated through a series of ethanol washes, incubated in 100% chloroform for 5 minutes, and then rinsed in 100% ethanol for 1 minute and 95% ethanol for 1 minute and allowed to air dry.

5 Hybridizations were performed with ³⁵S-radiolabeled (5 X 10⁷ cpm/ml) cRNA probes. Probes were incubated in the presence of a solution containing 600 mM NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA, 0.01% sheared salmon sperm DNA, 0.01% yeast tRNA, 0.05% yeast total RNA type X1, 1 X Denhardt's solution, 50% formamide, 10% dextran sulfate, 100 mM dithiothreitol, 0.1% sodium dodecyl sulfate (SDS), and 0.1% sodium
10 thiosulfate for 18 hours at 55°C.

After hybridization, slides were washed with 2 X SSC. Sections were then sequentially incubated at 37°C in TNE (a solution containing 10 mM Tris-HCl (pH 7.6), 500 mM NaCl, and 1 mM EDTA), for 10 minutes, in TNE with 10µg of RNase A per ml for 30 minutes, and finally in TNE for 10 minutes. Slides were then rinsed with 2 X SSC at room
15 temperature, washed with 2 X SSC at 50°C for 1 hour, washed with 0.2 X SSC at 55°C for 1 hour, and 0.2 X SSC at 60°C for 1 hour. Sections were then dehydrated rapidly through serial ethanol-0.3 M sodium acetate concentrations before being air dried and exposed to Kodak Biomax MR scientific imaging film for 24 hours and subsequently dipped in NB-2 photoemulsion and exposed at 4°C for 7 days before being developed and counter stained.

20 A 5kb NIP2b transcript is predominantly expressed in the brain, but on longer exposures this transcript can also be detected in prostate and small intestine. An additional 4kb transcript can also be detected in the heart and skeletal muscle on longer exposures. Within the brain, NIP2b is expressed in most regions. The following areas give a particularly strong signal: cortex, amygdala, striatum, hippocampus, substantia nigra, corpus
25 callosum, cerebellum (Purkinje cells), striatum, basal forebrain, lateral eniculate nucleus, and facial nucleus (motor neurons).

The NIP2cL transcript is predominantly expressed in the brain, but can also be detected in the prostate, colon and small intestine. On longer exposures, this transcript can also be detected in the heart, placenta, kidney, pancreas, spleen, testes, ovary and skeletal
30 muscle. In addition, numerous other small transcripts can be seen on longer exposures. Within the brain, NIP2cL is expressed in the following regions: cortex, amygdala, cerebellum (granule cells), hippocampus (dentate gyrus and hippocampal pyramidal cells), striatum, thalamus, locus coeruleus, lateral geniculate nucleus, and facial nucleus (motor neurons).

35 The NIP2cS transcript is predominantly expressed in the heart, skeletal muscle, and brain.

**EXAMPLE 2: EXPRESSION OF RECOMBINANT NIP2b, NIP2cL,
AND NIP2cS PROTEIN IN BACTERIAL CELLS**

In this example, NIP2b, NIP2cL, and NIP2cS is expressed as a recombinant
5 glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide is
isolated and characterized. Specifically, NIP2b, NIP2cL, and NIP2cS is fused to GST and
this fusion polypeptide is expressed in *E. coli*, e.g., strain PEB199. Expression of the GST-
NIP2b, NIP2cL, and NIP2cS fusion protein in PEB199 is induced with IPTG. The
10 recombinant fusion polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel
electrophoretic analysis of the polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.

**EXAMPLE 3: EXPRESSION OF RECOMBINANT NIP2b, NIP2cL,
15 AND NIP2cS PROTEIN IN COS CELLS**

To express the NIP2b, NIP2cL, and NIP2cS gene in COS cells, the pcDNA/Amp
vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40
origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV
20 promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A
DNA fragment encoding the entire NIP2b, NIP2cL, and NIP2cS protein and an HA tag
(Wilson et al. (1984) *Cell* 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment
is cloned into the polylinker region of the vector, thereby placing the expression of the
recombinant protein under the control of the CMV promoter.

25 To construct the plasmid, the NIP2b, NIP2cL, and NIP2cS DNA sequence is
amplified by PCR using two primers. The 5' primer contains the restriction site of interest
followed by approximately twenty nucleotides of the NIP2b, NIP2cL, and NIP2cS coding
sequence starting from the initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation stop codon, the HA tag or
30 FLAG tag and the last 20 nucleotides of the NIP2b, NIP2cL, and NIP2cS coding sequence.
The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate
restriction enzymes and the vector is dephosphorylated using the CIAP enzyme (New
England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so
that the NIP2b, NIP2cL, and NIP2cS gene is inserted in the correct orientation. The ligation
35 mixture is transformed into *E. coli* cells (strains HB101, DH5a, SURE, available from
Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on
ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from
transformants and examined by restriction analysis for the presence of the correct fragment.

COS cells are subsequently transfected with the NIP2b, NIP2cL, and NIP2cS-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the NIP2b, NIP2cL, and NIP2cS polypeptide is detected by radiolabelling (³⁵S-methionine or ³⁵S-cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labelled for 8 hours with ³⁵S-methionine (or ³⁵S-cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated polypeptides are then analyzed by SDS-PAGE.

Alternatively, DNA containing the NIP2b, NIP2cL, and NIP2cS coding sequence is cloned directly into the polylinker of the pcDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the NIP2b, NIP2cL, and NIP2cS polypeptide is detected by radiolabelling and immunoprecipitation using a NIP2b, NIP2cL, and NIP2cS specific monoclonal antibody.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

<110> Rory A.J. Curtis and M. Alexandra Glucksmann

5 <120> Isolated Proteins and Nucleic Acid Molecules Having
Homology to NIP2 Proteins and Uses Thereof

<130> mni061

10 <140>
<141>

<160> 9

15 <170> PatentIn Ver. 2.0

<210> 1
<211> 3076
<212> DNA

20 <213> Homo sapiens

<220>
<221> CDS
<222> (370) .. (1482)

25 <400> 1
ccacgcgtcc gccacgcgt ccggaagaa gcagctacct cggaggcagg gcgcgcaggc 60
gggcggcgat gagagggggc gcagccgcag ccccgcgctg gggagcccac cgctaaccct 120
30 gcaccccacc caccctgca caaaagagct ggcgggcgct ggccacgtcg ccctgggtga 180
ccttcctcgg atgcagaatc cgcccctgcg agcatcctct tcctcctagg ctctgaaggc 240
35 ccggggagcg tgagcgatgc ccagctgcac ccgggcaggg ctgcgcctttg tttgccagta 300
aggaggagag gctgtctcag ctgcagaggg gtcacccctg cttcaagcca gtgcctcttc 360
ccagctccc atg ggg acc acc gaa gcc acg ctc cgg atg gaa aac gtg gac 411
40 Met Gly Thr Thr Glu Ala Thr Leu Arg Met Glu Asn Val Asp
1 5 10
gtg aag gag gaa tgg cag gac gaa gat ctt ccc agg cca ctc cca gaa 459
Val Lys Glu Glu Trp Gln Asp Glu Asp Leu Pro Arg Pro Leu Pro Glu
45 15 20 25 30
gag acg ggg gtg gaa ctg ctt ggc agc ccg gtg gaa gac aca tcc tct 507
Glu Thr Gly Val Glu Leu Leu Gly Ser Pro Val Glu Asp Thr Ser Ser
35 40 45
50 cct ccc aac acg cta aat ttc aac gga gcg cat cgt aag agg aag acg 555
Pro Pro Asn Thr Leu Asn Phe Asn Gly Ala His Arg Lys Arg Lys Thr
50 55 60
55 ctg gtg gcc cca gag atc aac att tct ctg gat cag agt gag ggg tcc 603
Leu Val Ala Pro Glu Ile Asn Ile Ser Leu Asp Gln Ser Glu Gly Ser
65 70 75

	ctg	ctg	tcc	gat	gac	ttc	ttg	gat	acc	cct	gat	gac	ctg	gat	att	aac	651
	Leu	Leu	Ser	Asp	Asp	Phe	Leu	Asp	Thr	Pro	Asp	Asp	Leu	Asp	Ile	Asn	
		80					85					90					
5	gtg	gat	gac	atc	gag	acc	ccc	gat	gag	acc	gac	tcg	ctg	gag	ttc	ctg	699
	Val	Asp	Asp	Ile	Glu	Thr	Pro	Asp	Glu	Thr	Asp	Ser	Leu	Glu	Phe	Leu	
	95				100					105					110		
10	ggg	aat	ggc	aac	gaa	ctg	gag	tgg	gaa	gac	gac	acc	ccc	gtg	gcc	acc	747
	Gly	Asn	Gly	Asn	Glu	Leu	Glu	Trp	Glu	Asp	Asp	Thr	Pro	Val	Ala	Thr	
					115					120					125		
15	gcc	aag	aac	atg	ccc	ggg	gac	agc	gcg	gat	cta	ttt	ggg	gac	ggc	acg	795
	Ala	Lys	Asn	Met	Pro	Gly	Asp	Ser	Ala	Asp	Leu	Phe	Gly	Asp	Gly	Thr	
				130					135					140			
20	acg	gag	gac	ggc	agc	gcc	gcc	aac	ggg	cgc	ctg	tgg	cgg	aca	gtg	atc	843
	Thr	Glu	Asp	Gly	Ser	Ala	Ala	Asn	Gly	Arg	Leu	Trp	Arg	Thr	Val	Ile	
			145						150				155				
25	atc	ggg	gag	caa	gag	cac	cgt	ata	gac	ctg	cac	atg	atc	cgg	cct	tac	891
	Ile	Gly	Glu	Gln	Glu	His	Arg	Ile	Asp	Leu	His	Met	Ile	Arg	Pro	Tyr	
	160						165					170					
30	atg	aaa	gtg	gtc	acc	cac	gga	ggg	tac	tac	ggc	gaa	ggc	ctc	aac	gcc	939
	Met	Lys	Val	Val	Thr	His	Gly	Gly	Tyr	Tyr	Gly	Glu	Gly	Leu	Asn	Ala	
	175					180					185					190	
35	tac	cac	tac	atc	atg	gag	aac	ctc	ttc	ctg	tac	gtc	atc	agc	agc	tta	1035
	Tyr	His	Tyr	Ile	Met	Glu	Asn	Leu	Phe	Leu	Tyr	Val	Ile	Ser	Ser	Leu	
				210					215					220			
40	gag	ctc	ctg	gtg	gct	gag	gac	tac	atg	atc	gtg	tac	ctg	aac	ggg	gcc	1083
	Glu	Leu	Leu	Val	Ala	Glu	Asp	Tyr	Met	Ile	Val	Tyr	Leu	Asn	Gly	Ala	
			225					230					235				
45	acg	ccc	cgg	cgg	agg	atg	cct	gga	atc	ggc	tgg	ctg	aag	aag	tgc	tac	1131
	Thr	Pro	Arg	Arg	Arg	Met	Pro	Gly	Ile	Gly	Trp	Leu	Lys	Lys	Cys	Tyr	
		240					245					250					
50	cag	atg	atc	gac	cgg	agg	ttg	cgg	aaa	aac	ctg	aag	tcc	ttg	atc	atc	1179
	Gln	Met	Ile	Asp	Arg	Arg	Leu	Arg	Lys	Asn	Leu	Lys	Ser	Leu	Ile	Ile	
	255					260					265					270	
55	gtc	cac	ccc	tcg	tgg	ttc	att	cgg	act	gtg	ctg	gcc	atc	tct	cgc	cct	1227
	Val	His	Pro	Ser	Trp	Phe	Ile	Arg	Thr	Val	Leu	Ala	Ile	Ser	Arg	Pro	
					275					280					285		
60	ttc	atc	agc	gtc	aag	ttc	atc	aac	aag	atc	cag	tac	gtg	cac	agc	ttg	1275
	Phe	Ile	Ser	Val	Lys	Phe	Ile	Asn	Lys	Ile	Gln	Tyr	Val	His	Ser	Leu	
				290					295					300			

gaa gac ctg gag caa ctc atc cct atg gaa cac gtc cag atc cca gac 1323
 Glu Asp Leu Glu Gln Leu Ile Pro Met Glu His Val Gln Ile Pro Asp
 305 310 315

5 tgc gtc ctg caa tac gaa gag gaa aga ctg aag gcc agg agg gag agc 1371
 Cys Val Leu Gln Tyr Glu Glu Glu Arg Leu Lys Ala Arg Arg Glu Ser
 320 325 330

10 gcg agg ccc cag ccg gag ttt gtg ctg ccc agg tct gaa gag aag cca 1419
 Ala Arg Pro Gln Pro Glu Phe Val Leu Pro Arg Ser Glu Glu Lys Pro
 335 340 345 350

15 gag gtg gca cca gtg gaa aac agg tct gct ctg gtc tca gaa gat cag 1467
 Glu Val Ala Pro Val Glu Asn Arg Ser Ala Leu Val Ser Glu Asp Gln
 355 360 365

gaa aca agc atg tcc tgaggcgacg tgagcataac aaaggacatg gaagaagatt 1522
 Glu Thr Ser Met Ser
 370

20 ccagatgcc aaaaacctct gtcagacgcc cactggcccc agatctcatc ctgcctcatc 1582
 ctgagtccca atcttccaag ggtgccagcc cctccgttca tctctgaaac ccagcatcct 1642

25 tttcagctgc ttgaaaacat tgtatttttt ttttttaacg atgcagtatt tgtgcgttcc 1702
 agaaaagggc ccagctctga gcccctcacc cttccacact cacgaaactct cagccgagga 1762

30 aggcaagaag cgcagggggg ggcccgcgtg gcgtcgggtg cctccgctcc tgctcgcagc 1822
 cctgtgggtc agagctggat acaagattca agacccttct cttgcttgtc acccgctcca 1882

35 gggtggagcc acagacaccc accgccaccc cggctgggtc tgcgtccttt cctgtgcctt 1942
 tccctocaga atgcggcctc agacctagaa gctcaacccc cctatgaggg ccacgtcctg 2002

40 gggtagctcc tgacctccga ctttatgtcc aaatttcaca cccatggttt ttcatttgac 2062
 ccgccccctt ctgcctcata atgacaccca gtcctttga gaggatcaga gccattgca 2122

45 caagaagagc cgctgccaac catccttgtc ctccgattgc aaaatgacac ccagtaatc 2182
 tagaacattc tcaagcccct ttaactcaga tgtcaagcca ccgggcaaac cccgtcaata 2242

50 cctcccacca agaatgaga tatgtggacc tactgtctcc cccaacccag cgtcaggctg 2302
 ggacacgcca acgctgttcc gggttggaac agcacaggct cagaaactgg ctctgaaata 2362

55 ggcagaccta gcaagaggaa gatacagggc atcgggcgtt tgagtgtttc agaagtcatt 2422
 cgggaagata aatccagtgc gctggccgca gccacctgca ttcaaagctt ggaccagcgg 2482

gttcttggtc gggaggcaaa tttccctagg aaaaagaaga cagacttttc taatgggggtc 2542

60 caaatgcgga tcaactggtc gatggactct agaagcactg agctccctgt ctctggaagt 2602
 atttaagaaa aggctggggc aggcacgatg gctcacgcct gtaatcccag actttggggag 2662

gcccaggcag gcggatcacc tgaggtagagg agtttgagaa cagcctggcc aacatggtga 2722
 5 aacctcatct ctactaaaaa tacaaaaatt agccaggcgt ggtggcaggt gcctgtaatc 2782
 ccagctactt gggaggctga ggcattgagaa tcaactaaac ctgagaggca gaggttacag 2842
 tgagccaaga tcgtgccact gcattccagc ctgggcgaca gagcaagact ctgtctcaaa 2902
 10 aaaaataaaa aataatcagg gcacagtggc tcatgcctgt aatcccagca ctctgggagg 2962
 ctgaggtggg tggatcacct gaggtcagga gttcaagacc agcctggtga acatggcgaa 3022
 acccgtctc taataaaaat acaaaaatta gccgggcatg gtggtgcatg cctg 3076

15

<210> 2

<211> 371

<212> PRT

20 <213> Homo sapiens

<400> 2

Met Gly Thr Thr Glu Ala Thr Leu Arg Met Glu Asn Val Asp Val Lys
 1 5 10 15
 25 Glu Glu Trp Gln Asp Glu Asp Leu Pro Arg Pro Leu Pro Glu Glu Thr
 20 25 30
 30 Gly Val Glu Leu Leu Gly Ser Pro Val Glu Asp Thr Ser Ser Pro Pro
 35 35 40 45
 Asn Thr Leu Asn Phe Asn Gly Ala His Arg Lys Arg Lys Thr Leu Val
 50 55 60
 35 Ala Pro Glu Ile Asn Ile Ser Leu Asp Gln Ser Glu Gly Ser Leu Leu
 65 70 75 80
 Ser Asp Asp Phe Leu Asp Thr Pro Asp Asp Leu Asp Ile Asn Val Asp
 85 90 95
 40 Asp Ile Glu Thr Pro Asp Glu Thr Asp Ser Leu Glu Phe Leu Gly Asn
 100 105 110
 45 Gly Asn Glu Leu Glu Trp Glu Asp Asp Thr Pro Val Ala Thr Ala Lys
 115 120 125
 Asn Met Pro Gly Asp Ser Ala Asp Leu Phe Gly Asp Gly Thr Thr Glu
 130 135 140
 50 Asp Gly Ser Ala Ala Asn Gly Arg Leu Trp Arg Thr Val Ile Ile Gly
 145 150 155 160
 Glu Gln Glu His Arg Ile Asp Leu His Met Ile Arg Pro Tyr Met Lys
 165 170 175
 55 Val Val Thr His Gly Gly Tyr Tyr Gly Glu Gly Leu Asn Ala Ile Ile
 180 185 190

366T01:CEB42160

	Val	Phe	Ala	Ala	Cys	Phe	Leu	Pro	Asp	Ser	Ser	Leu	Pro	Asp	Tyr	His	
			195					200					205				
5	Tyr	Ile	Met	Glu	Asn	Leu	Phe	Leu	Tyr	Val	Ile	Ser	Ser	Leu	Glu	Leu	
		210					215					220					
	Leu	Val	Ala	Glu	Asp	Tyr	Met	Ile	Val	Tyr	Leu	Asn	Gly	Ala	Thr	Pro	
	225					230					235					240	
10	Arg	Arg	Arg	Met	Pro	Gly	Ile	Gly	Trp	Leu	Lys	Lys	Cys	Tyr	Gln	Met	
				245						250					255		
	Ile	Asp	Arg	Arg	Leu	Arg	Lys	Asn	Leu	Lys	Ser	Leu	Ile	Ile	Val	His	
15				260					265					270			
	Pro	Ser	Trp	Phe	Ile	Arg	Thr	Val	Leu	Ala	Ile	Ser	Arg	Pro	Phe	Ile	
			275					280					285				
20	Ser	Val	Lys	Phe	Ile	Asn	Lys	Ile	Gln	Tyr	Val	His	Ser	Leu	Glu	Asp	
		290					295					300					
	Leu	Glu	Gln	Leu	Ile	Pro	Met	Glu	His	Val	Gln	Ile	Pro	Asp	Cys	Val	
	305					310					315					320	
25	Leu	Gln	Tyr	Glu	Glu	Glu	Arg	Leu	Lys	Ala	Arg	Arg	Glu	Ser	Ala	Arg	
				325						330					335		
	Pro	Gln	Pro	Glu	Phe	Val	Leu	Pro	Arg	Ser	Glu	Glu	Lys	Pro	Glu	Val	
30				340					345					350			
	Ala	Pro	Val	Glu	Asn	Arg	Ser	Ala	Leu	Val	Ser	Glu	Asp	Gln	Glu	Thr	
		355						360					365				
35	Ser	Met	Ser														
		370															
	<210>	3															
40	<211>	1113															
	<212>	DNA															
	<213>	Homo sapiens															
	<220>																
45	<221>	CDS															
	<222>	(1) .. (1113)															
	<400>	3															
50	atg	ggg	acc	acc	gaa	gcc	acg	ctc	cgg	atg	gaa	aac	gtg	gac	gtg	aag	48
	Met	Gly	Thr	Thr	Glu	Ala	Thr	Leu	Arg	Met	Glu	Asn	Val	Asp	Val	Lys	
	1				5					10				15			
	gag	gaa	tgg	cag	gac	gaa	gat	ctt	ccc	agg	cca	ctc	cca	gaa	gag	acg	96
55	Glu	Glu	Trp	Gln	Asp	Glu	Asp	Leu	Pro	Arg	Pro	Leu	Pro	Glu	Glu	Thr	
				20					25					30			

	ggg gtg gaa ctg ctt ggc agc ccg gtg gaa gac aca tcc tct cct ccc	144
	Gly Val Glu Leu Leu Gly Ser Pro Val Glu Asp Thr Ser Ser Pro Pro	
	35 40 45	
5	aac acg cta aat ttc aac gga gcg cat cgt aag agg aag acg ctg gtg	192
	Asn Thr Leu Asn Phe Asn Gly Ala His Arg Lys Arg Lys Thr Leu Val	
	50 55 60	
10	gcc cca gag atc aac att tct ctg gat cag agt gag ggg tcc ctg ctg	240
	Ala Pro Glu Ile Asn Ile Ser Leu Asp Gln Ser Glu Gly Ser Leu Leu	
	65 70 75 80	
15	tcc gat gac ttc ttg gat acc cct gat gac ctg gat att aac gtg gat	288
	Ser Asp Asp Phe Leu Asp Thr Pro Asp Asp Leu Asp Ile Asn Val Asp	
	85 90 95	
20	gac atc gag acc ccc gat gag acc gac tcg ctg gag ttc ctg ggg aat	336
	Asp Ile Glu Thr Pro Asp Glu Thr Asp Ser Leu Glu Phe Leu Gly Asn	
	100 105 110	
25	ggc aac gaa ctg gag tgg gaa gac gac acc ccc gtg gcc acc gcc aag	384
	Gly Asn Glu Leu Glu Trp Glu Asp Asp Thr Pro Val Ala Thr Ala Lys	
	115 120 125	
30	aac atg ccc ggg gac agc gcg gat cta ttt ggg gac ggc acg acg gag	432
	Asn Met Pro Gly Asp Ser Ala Asp Leu Phe Gly Asp Gly Thr Thr Glu	
	130 135 140	
35	gac ggc agc gcc gcc aac ggg cgc ctg tgg cgg aca gtg atc atc ggg	480
	Asp Gly Ser Ala Ala Asn Gly Arg Leu Trp Arg Thr Val Ile Ile Gly	
	145 150 155 160	
40	gag caa gag cac cgt ata gac ctg cac atg atc cgg cct tac atg aaa	528
	Glu Gln Glu His Arg Ile Asp Leu His Met Ile Arg Pro Tyr Met Lys	
	165 170 175	
45	gtg gtc acc cac gga ggg tac tac ggc gaa ggc ctc aac gcc atc atc	576
	Val Val Thr His Gly Gly Tyr Tyr Gly Glu Gly Leu Asn Ala Ile Ile	
	180 185 190	
50	gtc ttc gca gcc tgc ttc ctt cca gac agc agc ctc ccc gac tac cac	624
	Val Phe Ala Ala Cys Phe Leu Pro Asp Ser Ser Leu Pro Asp Tyr His	
	195 200 205	
55	tac atc atg gag aac ctc ttc ctg tac gtc atc agc agc tta gag ctc	672
	Tyr Ile Met Glu Asn Leu Phe Leu Tyr Val Ile Ser Ser Leu Glu Leu	
	210 215 220	
60	ctg gtg gct gag gac tac atg atc gtg tac ctg aac ggt gcc acg ccc	720
	Leu Val Ala Glu Asp Tyr Met Ile Val Tyr Leu Asn Gly Ala Thr Pro	
	225 230 235 240	
65	cgg cgg agg atg cct gga atc ggc tgg ctg aag aag tgc tac cag atg	768
	Arg Arg Arg Met Pro Gly Ile Gly Trp Leu Lys Lys Cys Tyr Gln Met	
	245 250 255	

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted October 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

atc gac cgg agg ttg cgg aaa aac ctg aag tcc ttg atc atc gtc cac 816
Ile Asp Arg Arg Leu Arg Lys Asn Leu Lys Ser Leu Ile Ile Val His
260 265 270

5 ccc tcg tgg ttc att cgg act gtg ctg gcc atc tct cgc cct ttc atc 864
Pro Ser Trp Phe Ile Arg Thr Val Leu Ala Ile Ser Arg Pro Phe Ile
275 280 285

10 agc gtc aag ttc atc aac aag atc cag tac gtg cac agc ttg gaa gac 912
Ser Val Lys Phe Ile Asn Lys Ile Gln Tyr Val His Ser Leu Glu Asp
290 295 300

15 ctg gag caa ctc atc cct atg gaa cac gtc cag atc cca gac tgc gtc 960
Leu Glu Gln Leu Ile Pro Met Glu His Val Gln Ile Pro Asp Cys Val
305 310 315 320

20 ctg caa tac gaa gag gaa aga ctg aag gcc agg agg gag agc gcg agg 1008
Leu Gln Tyr Glu Glu Glu Arg Leu Lys Ala Arg Arg Glu Ser Ala Arg
325 330 335

ccc cag ccg gag ttt gtg ctg ccc agg tct gaa gag aag cca gag gtg 1056
Pro Gln Pro Glu Phe Val Leu Pro Arg Ser Glu Glu Lys Pro Glu Val
340 345 350

25 gca cca gtg gaa aac agg tct gct ctg gtc tca gaa gat cag gaa aca 1104
Ala Pro Val Glu Asn Arg Ser Ala Leu Val Ser Glu Asp Gln Glu Thr
355 360 365

30 agc atg tcc 1113
Ser Met Ser
370

35 <210> 4
<211> 4235
<212> DNA
<213> Homo sapiens

40 <220>
<221> CDS
<222> (23)..(988)

45 <400> 4
gtcgacccac gcgtccgcgg aa atg gag gag gag aca gag ttc ctt gag ctc 52
Met Glu Glu Glu Thr Glu Phe Leu Glu Leu
1 5 10

50 gga acc agg ata tca aga cca aat gga cta ctg tca gag gat gta gga 100
Gly Thr Arg Ile Ser Arg Pro Asn Gly Leu Leu Ser Glu Asp Val Gly
15 20 25

atg gac atc ccc ttt gaa gag ggc gtg ctg agt ccc agt gct gca gac 148
Met Asp Ile Pro Phe Glu Glu Gly Val Leu Ser Pro Ser Ala Ala Asp
30 35 40

bioRxiv preprint doi: <https://doi.org/10.1101/201702>; this version posted February 2, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	atg	agg	cct	gaa	cct	cct	aat	tct	ctg	gat	ctt	aat	gac	act	cat	cct	196
	Met	Arg	Pro	Glu	Pro	Pro	Asn	Ser	Leu	Asp	Leu	Asn	Asp	Thr	His	Pro	
			45					50					55				
5	cgg	aga	atc	aag	ctc	aca	gcc	cca	aat	atc	aat	ctt	tct	ctg	gac	caa	244
	Arg	Arg	Ile	Lys	Leu	Thr	Ala	Pro	Asn	Ile	Asn	Leu	Ser	Leu	Asp	Gln	
		60					65					70					
10	agt	gaa	gga	tct	att	ctc	tct	gat	gat	aac	ttg	gac	agt	cca	gat	gaa	292
	Ser	Glu	Gly	Ser	Ile	Leu	Ser	Asp	Asp	Asn	Leu	Asp	Ser	Pro	Asp	Glu	
		75				80					85					90	
15	att	gac	atc	aat	gtg	gat	gaa	ctt	gat	acc	ccc	gat	gaa	gca	gat	tct	340
	Ile	Asp	Ile	Asn	Val	Asp	Glu	Leu	Asp	Thr	Pro	Asp	Glu	Ala	Asp	Ser	
					95					100					105		
20	ttt	gag	tac	act	ggc	cat	gat	ccc	aca	gcc	aac	aaa	gat	tct	ggc	caa	388
	Phe	Glu	Tyr	Thr	Gly	His	Asp	Pro	Thr	Ala	Asn	Lys	Asp	Ser	Gly	Gln	
				110					115					120			
25	gag	tca	gag	tct	att	cca	gaa	tat	acg	gcc	gaa	gag	gaa	cgg	gag	gac	436
	Glu	Ser	Glu	Ser	Ile	Pro	Glu	Tyr	Thr	Ala	Glu	Glu	Glu	Arg	Glu	Asp	
			125					130					135				
30	aac	cgg	ctt	tgg	atg	aca	gtg	gtc	att	gga	gaa	caa	gag	cag	cgc	att	484
	Asn	Arg	Leu	Trp	Met	Thr	Val	Val	Ile	Gly	Glu	Gln	Glu	Gln	Arg	Ile	
		140					145					150					
35	gat	tca	gga	tac	tat	ggg	gac	ggg	cta	aat	gcc	atc	att	gtg	ttt	gcc	580
	Asp	Ser	Gly	Tyr	Tyr	Gly	Asp	Gly	Leu	Asn	Ala	Ile	Ile	Val	Phe	Ala	
					175					180					185		
40	gcc	tgt	ttt	ctg	cca	gac	agc	agt	cgg	gcg	gat	tac	cac	tat	gtc	atg	628
	Ala	Cys	Phe	Leu	Pro	Asp	Ser	Ser	Arg	Ala	Asp	Tyr	His	Tyr	Val	Met	
			190						195					200			
45	gaa	aat	ctt	ttc	cta	tat	gta	ata	agt	act	tta	gag	ttg	atg	gta	gct	676
	Glu	Asn	Leu	Phe	Leu	Tyr	Val	Ile	Ser	Thr	Leu	Glu	Leu	Met	Val	Ala	
			205					210					215				
50	gaa	gac	tat	atg	att	gtg	tac	ttg	aat	ggg	gca	acc	cca	aga	agg	agg	724
	Glu	Asp	Tyr	Met	Ile	Val	Tyr	Leu	Asn	Gly	Ala	Thr	Pro	Arg	Arg	Arg	
		220					225					230					
55	atg	cca	ggg	cta	ggc	tgg	atg	aag	aaa	tgc	tac	cag	atg	att	gac	aga	772
	Met	Pro	Gly	Leu	Gly	Trp	Met	Lys	Lys	Cys	Tyr	Gln	Met	Ile	Asp	Arg	
		235				240					245				250		
60	cgg	ttg	agg	aag	aat	ttg	aaa	tca	ttc	atc	att	gtt	cat	cca	tct	tgg	820
	Arg	Leu	Arg	Lys	Asn	Leu	Lys	Ser	Phe	Ile	Ile	Val	His	Pro	Ser	Trp	
					255					260					265		

ttc atc aga aca atc ctt gct gtg aca cga cct ttt ata agt tca aaa 868
Phe Ile Arg Thr Ile Leu Ala Val Thr Arg Pro Phe Ile Ser Ser Lys
270 275 280

5 ttc agc agt aaa att aaa tat gtc aat agc tta tca gaa ctc agt ggg 916
Phe Ser Ser Lys Ile Lys Tyr Val Asn Ser Leu Ser Glu Leu Ser Gly
285 290 295

10 ctg atc cca atg gat tgc atc cac att cca gag agc atc atc aat att 964
Leu Ile Pro Met Asp Cys Ile His Ile Pro Glu Ser Ile Ile Asn Ile
300 305 310

15 gac ttg aag ctg aaa gaa aag cct tagttggcca tgctggaaga agaggatgct 1018
Asp Leu Lys Leu Lys Glu Lys Pro
315 320

20 tttctggttc atggttctgt tgaaacatat ctacctgaaa gagacagggc tgatgttacc 1078
tttttccact ttgcactacc tgggtgccatt ctaaattttct aaggggaaaa atagaaagtt 1138
tgtttactct taagatatatt tatgaaattg tgtgtacttt cctattttgc caattatgtg 1198
cctcaaagat tttagttgag ccttagcaag aaagtaggac cttccatttc aatacttcat 1258

25 taacacggtg tagtgatact ttgtccctta gactggtggt taccagtaag ataccttta 1318
tccactgtta agtatgagt gatttgtttc catagattag ctggatttcc ttttggtgat 1378
tgcattaggt ttaaagtaca caggtctcaa ctctccccag gaaagtttcc cctgtttgac 1438

30 tccaccttta aaatcctaag cctgactagg acagccacaa accacacaag gtgtaaaacc 1498
atcatcagct aagtgcccggt tttgttcttg tttaccagaa tctccttta cttctcaaag 1558

35 ggaagccggg ctttctaata cacgtcaact ttatttttagt tgtcaaattg ggcattatat 1618
tttatgtaaa ttggtctttt aacatcattt tctgatgaa tgttggtgac caccacattg 1678
tgaaatttaa gaatccgtgt tgcattgttg gtagctctct gagtttcagg ccataaactc 1738

40 agctccagag gttacctttt aagtgccaaag aactcaagt caaggtggcc tactcaaaaa 1798
tcatttggtg gcattcagtt attcatgaat tctctctctg catgcattat aaaaagtgat 1858

45 ctgcttttaa acaccgtaat ctgatcatag gcttaaaatt aaatatgagt attactttca 1918
tgtacaaaat atttccttta tagtcttcat atgcccttta aaatgccaac aagatttcaa 1978
gtctgtaggc ctctagttag gtgggggtgg aaaccacagc taagtctcgc tcaccactgc 2038

50 aagctaagaa tggtttttac attttgggtt ggaaaaattt tttttgaata tttcatgaca 2098
catgaaaatt attcaaatgt tagtgccgat aaataaagt gtactgaaac acagccacac 2158

55 aaacttgttt ttgtactgtc tacagctact ttcacactac agccgcagag ctgagcagtt 2218
cagcagaccg tatgtccac aatgcctaaa acattgacta tgtttacaga aaaagtttgc 2278

tgacccctgc tctagcaaac gcaccccttc ctactccacc ccaatttgta tttagatagt 2338
5 tttctctaaca gaacggacaa atgaggctgc aaactaattt atttttgtca aaaatcaatg 2398
ttttgacatc cacagacagt gaaataaaaag aaatggcttg ctgaaaaaca tgaggagtcc 2458
tagccacaaa atcactgctt aggttgcaat tgccaaaatg aagccttctt agaagcactt 2518
10 ctttagtata tacagggtgtt ggctgaagtc cgtgcctcac tctgggaacc attcttagtc 2578
tccagtgtct cctattacaa agaagctggc agaaataaaa atgaaggggt gagagcgggt 2638
ccaccctagt ctcatggtgg aaaattcatt ggggagagct gtccaggata tttggagtcc 2698
15 tgggtagaag gagcttgtaa ctactttaaa gtcgacatct ttgcacaggt gattgagttt 2758
ctctgacctc attgcttcac ctctgtctcc tcccgctctt cgcacgtgc ccacacacac 2818
20 gcagttcagc cctctttcct ccataagcct ccctcgtttt ctcttttctc ctcttgatcc 2878
tttcaagcga gtatcttggt gaattgtatg ttctgttgga tctcctcctt cataacatct 2938
ggcttggttg acagaaaaac cctacagccc acccctccc acagcccacc tccacttttg 2998
25 aaagcccaaa ttacacctct ccagaacac agtggtgacg taaatacagt taccatata 3058
tctgtttgt tcacctattt gctactttca ctcatgagca tccattttg taaaatgaat 3118
30 tccatggtca ccctgtcaca ggaagtaatg aaaaatccag tgttcagtgt agtggtgcaa 3178
acctgagggc atagagctgt tcatagaggg ctcttggtat agccaaacag acacagcaac 3238
aatctcacca tttatatata tatttttaac ttgtccagct catctatgga aaactactca 3298
35 ggtggatgc tgtttgaagc ctcatcttc tacatgaaaa ttatgggcat ttgtcccaat 3358
gattttgttt cagctgttct gtaggctgca taaccactct gatatttagg tatctgctat 3418
40 tttattatct taaaagacaa attaatttaa ttgcatgtgc tagggaaaag ctaccatgta 3478
cattcacccc aagtaaatag aatcctagat gaatcctaga aaaataatcc ctaagcagat 3538
aggtagacag aggtaaacat tcacatgatt tagctctcta gctcttgac tctgaacatt 3598
45 cttgcttttg ttctgacttc tgggaactgc tttgcatttc tcctatagat ctgtagttaa 3658
gggaaccaag gggtcattgg ggcaaaagca ttgtttctca aagctccttg attaagagaa 3718
50 agaacagaaa tttgcacaga agatagtgtc aaggagtgag aaagtttggt tgagggcagt 3778
agctcagtgt ggaagaaaat cctgaagttt ctgttgaagc catacaatgt tctatgggggt 3838
tactctctaa gacattctct gaggtgtgtg aggaagtcac tactcctagc ctttgtttaag 3898
55 atgtaatttt aaatattcag ttatgggtact atgtttgcaa ctctcgtctt atcacaatgc 3958

10

<212> PRT

15

20

25

30

35

40

45

50

55

Ser Ser Arg Ala Asp Tyr His Tyr Val Met Glu Asn Leu Phe Leu Tyr
195 200 205

Val Ile Ser Thr Leu Glu Leu Met Val Ala Glu Asp Tyr Met Ile Val
 210 215 220

5 Tyr Leu Asn Gly Ala Thr Pro Arg Arg Arg Met Pro Gly Leu Gly Trp
 225 230 235 240

Met Lys Lys Cys Tyr Gln Met Ile Asp Arg Arg Leu Arg Lys Asn Leu
 245 250 255

10 Lys Ser Phe Ile Ile Val His Pro Ser Trp Phe Ile Arg Thr Ile Leu
 260 265 270

15 Ala Val Thr Arg Pro Phe Ile Ser Ser Lys Phe Ser Ser Lys Ile Lys
 275 280 285

Tyr Val Asn Ser Leu Ser Glu Leu Ser Gly Leu Ile Pro Met Asp Cys
 290 295 300

20 Ile His Ile Pro Glu Ser Ile Ile Asn Ile Asp Leu Lys Leu Lys Glu
 305 310 315 320

Lys Pro

25

<210> 6
 <211> 966
 <212> DNA
 30 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1) .. (966)

35

<400> 6
 atg gag gag gag aca gag ttc ctt gag ctc gga acc agg ata tca aga 48
 Met Glu Glu Glu Thr Glu Phe Leu Glu Leu Gly Thr Arg Ile Ser Arg
 1 5 10 15

40

cca aat gga cta ctg tca gag gat gta gga atg gac atc ccc ttt gaa 96
 Pro Asn Gly Leu Leu Ser Glu Asp Val Gly Met Asp Ile Pro Phe Glu
 20 25 30

45

gag ggc gtg ctg agt ccc agt gct gca gac atg agg cct gaa cct cct 144
 Glu Gly Val Leu Ser Pro Ser Ala Ala Asp Met Arg Pro Glu Pro Pro
 35 40 45

50

aat tct ctg gat ctt aat gac act cat cct cgg aga atc aag ctc aca 192
 Asn Ser Leu Asp Leu Asn Asp Thr His Pro Arg Arg Ile Lys Leu Thr
 50 55 60

55

gcc cca aat atc aat ctt tct ctg gac caa agt gaa gga tct att ctc 240
 Ala Pro Asn Ile Asn Leu Ser Leu Asp Gln Ser Glu Gly Ser Ile Leu
 65 70 75 80

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted October 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	tct	gat	gat	aac	ttg	gac	agt	cca	gat	gaa	att	gac	atc	aat	gtg	gat	288
	Ser	Asp	Asp	Asn	Leu	Asp	Ser	Pro	Asp	Glu	Ile	Asp	Ile	Asn	Val	Asp	
					85					90					95		
5																	
	gaa	ctt	gat	acc	ccc	gat	gaa	gca	gat	tct	ttt	gag	tac	act	ggc	cat	336
	Glu	Leu	Asp	Thr	Pro	Asp	Glu	Ala	Asp	Ser	Phe	Glu	Tyr	Thr	Gly	His	
				100					105					110			
10																	
	gat	ccc	aca	gcc	aac	aaa	gat	tct	ggc	caa	gag	tca	gag	tct	att	cca	384
	Asp	Pro	Thr	Ala	Asn	Lys	Asp	Ser	Gly	Gln	Glu	Ser	Glu	Ser	Ile	Pro	
			115					120					125				
15																	
	gaa	tat	acg	gcc	gaa	gag	gaa	cgg	gag	gac	aac	cgg	ctt	tgg	atg	aca	432
	Glu	Tyr	Thr	Ala	Glu	Glu	Glu	Arg	Glu	Asp	Asn	Arg	Leu	Trp	Met	Thr	
		130						135				140					
20																	
	gtg	gtc	att	gga	gaa	caa	gag	cag	cgc	att	gac	atg	aag	gtc	atc	gag	480
	Val	Val	Ile	Gly	Glu	Gln	Glu	Gln	Arg	Ile	Asp	Met	Lys	Val	Ile	Glu	
	145					150					155					160	
25																	
	ccc	tac	agg	aga	gtc	att	tct	cac	gga	gga	gat	tca	gga	tac	tat	ggg	528
	Pro	Tyr	Arg	Arg	Val	Ile	Ser	His	Gly	Gly	Asp	Ser	Gly	Tyr	Tyr	Gly	
				165						170					175		
30																	
	gac	ggt	cta	aat	gcc	atc	att	gtg	ttt	gcc	gcc	tgt	ttt	ctg	cca	gac	576
	Asp	Gly	Leu	Asn	Ala	Ile	Ile	Val	Phe	Ala	Ala	Cys	Phe	Leu	Pro	Asp	
				180					185					190			
35																	
	agc	agt	cgg	gcg	gat	tac	cac	tat	gtc	atg	gaa	aat	ctt	ttc	cta	tat	624
	Ser	Ser	Arg	Ala	Asp	Tyr	His	Tyr	Val	Met	Glu	Asn	Leu	Phe	Leu	Tyr	
			195					200					205				
40																	
	gta	ata	agt	act	tta	gag	ttg	atg	gta	gct	gaa	gac	tat	atg	att	gtg	672
	Val	Ile	Ser	Thr	Leu	Glu	Leu	Met	Val	Ala	Glu	Asp	Tyr	Met	Ile	Val	
		210					215					220					
45																	
	tac	ttg	aat	ggt	gca	acc	cca	aga	agg	agg	atg	cca	ggg	cta	ggc	tgg	720
	Tyr	Leu	Asn	Gly	Ala	Thr	Pro	Arg	Arg	Arg	Met	Pro	Gly	Leu	Gly	Trp	
	225					230					235					240	
50																	
	atg	aag	aaa	tgc	tac	cag	atg	att	gac	aga	cgg	ttg	agg	aag	aat		

atc cac att cca gag agc atc atc aat att gac ttg aag ctg aaa gaa 960
 Ile His Ile Pro Glu Ser Ile Ile Asn Ile Asp Leu Lys Leu Lys Glu
 305 310 315 320

5 aag cct 966
 Lys Pro

<210> 7
 10 <211> 2966
 <212> DNA
 <213> Homo sapiens

<220>
 15 <221> CDS
 <222> (56) .. (433)

<400> 7
 20 gtcgacccac gcgtccgggc gaatctgtat ttccagttaa ctgctcagaa gagag atg 58
 Met
 1

ctg aag agc tgt agt cgt gca tcc ttc tca ccc tcc gtt aga aag cct 106
 Leu Lys Ser Cys Ser Arg Ala Ser Phe Ser Pro Ser Val Arg Lys Pro
 5 10 15

cct ctc atc ctc aga aga cta ctg tca gag gat gta gga atg gac atc 154
 Pro Leu Ile Leu Arg Arg Leu Leu Ser Glu Asp Val Gly Met Asp Ile
 20 25 30

ccc ttt gaa gag ggc gtg ctg agt ccc agt gct gca gac atg agg cct 202
 Pro Phe Glu Glu Gly Val Leu Ser Pro Ser Ala Ala Asp Met Arg Pro
 35 40 45

gaa cct cct aat tct ctg gat ctt aat gac act cat cct cgg aga atc 250
 Glu Pro Pro Asn Ser Leu Asp Leu Asn Asp Thr His Pro Arg Arg Ile
 50 55 60 65

aag ctc aca gcc cca aat atc aat ctt tct ctg gac caa agt gaa gga 298
 Lys Leu Thr Ala Pro Asn Ile Asn Leu Ser Leu Asp Gln Ser Glu Gly
 70 75 80

tct att ctc tct gat gat aac ttg gac agt cca gat gaa att gac atc 346
 Ser Ile Leu Ser Asp Asp Asn Leu Asp Ser Pro Asp Glu Ile Asp Ile
 85 90 95

aat gtg gat gaa ctt gat acc ccc gat gaa gca gat tct ttt gag tac 394
 Asn Val Asp Glu Leu Asp Thr Pro Asp Glu Ala Asp Ser Phe Glu Tyr
 100 105 110

act ggc cat ggt aag tca cta agt tgg caa ggc caa agt taaatgctaa 443
 Thr Gly His Gly Lys Ser Leu Ser Trp Gln Gly Gln Ser
 115 120 125

55 ataagtaaaa gattttctaa cagacctctc atttttgtgc cagtggatcc tttttgtgat 503
 ttctagaagc ttctgttttt atttcagggtt ataggtggcc atgattgaca gtttggagcc 563

5
10
15
20
25
30
35
40
45
50
55

tgacagagaa agtatgggtc acagaggcca tacataacca ttgctcttta ttaaccccc 623
ctctgtgcta gcatttatgc taggcactgg ggctgagggg agactgttac atgctgtgtt 683
acaagaaacc tggggctggg tttgcagggg aagagaatth aatcaggatg ataaaatttg 743
aagaagagaa atcagagctt gccaatthct tgtataagtt cccactatct gcaatgttct 803
tttccccaga tccttacgtg actgactcct tctctthtatt cagatgttaa tcagatgtca 863
cctcctcaga gaagtcttcc ttgacctctg taatcaaaga tgcttcccac ttcccgaact 923
ccaccaccta gtcactctct gtcccagtgt tcattthtatt ttccacgtat cactaattca 983
aattgtatta tthtaactatt tgthtgcatc thtattgtct thctcttacc actcgaatgt 1043
atgctccaca ggagcaagga cthtatath gatcctgcgt ctccaataaa gtgggaagga 1103
aggaagggat ggtthtagggg gagtgaagaa aatgataaaa aagaagataa thaaaagtht 1163
tcagatcatc caagactgac actcctgata tgaacttcag thththcttta gthththctc 1223
thactctatg aaatctggtt taagaaatat gtacaaatac aatcaththt ththaaatgg 1283
cattatgtag ththctgtht agthctagcc agggtggaat thcttgaaat tataatatht 1343
gaaagtgaag gcgagagagt ctgggacaca gctattgctt thattcatht thaaaattca 1403
cgcaatctta aaagcaatac agtgccacaa thaatgggtg gcctgactth tagagacatg 1463
ctaattctag cagthccact cctagaagag cataattaga aaattcacca aattagctaa 1523
thattthcaac caatgggtcat tgagccgaca tgagcagtg agthcagact ctacctgac 1583
agagcttaag gctththth ctcaaaaagg aaatggctaa acgactgtt thatatgtct 1643
thatgcttaa gtagagthth thththththc ataagthatt ggggtacagg tggththtg 1703
thacatgagt aagththth gtgtaagtag agaththata thgcaththt atcatgtgtg 1763
aaththctgta gththctggg tagthgattc ttaggttgaa aatacacaaa taggaggtga 1823
aagaaggtct ggaaththgt ctaththctg tcatcccaga gagtcttcag cagctcctct 1883
atccatccca gthgccccct accagctcct gctcctthth ctgctaatat attgaccaa 1943
thccacagaa gactgtggca tgacccaact ggccccctc thgcctccg ththtgctc 2003
ctththgtca ggagagctth gtcacaccac atctgaacct ththththta aacatagtaa 2063
aactgtcgag caaagcagtg gtggctgggc aagctggtaa thaacactgc cacttgctga 2123
catggctctt thaatgtagt taacatagct gtgttgaaag aaccagthta atggccacaa 2183
ccctgththta ggtctthaat gcaaaggaca gaattgthaa ctaagthgaa thththaaatc 2243

taccttaatt ttcaaatgaa agatatatag tcagaggttg aaactttgaa aacacaaagt 2303
gcctctgaat agctatattt tgtaaactg aggacatgga taagtgactg tataagaggg 2363
5 ttggattata aatatgtttg agttctgaag tatgaaataa atgcttgaaa gcagcctggt 2423
tcttaggttt ctcacgcgac cattttgaac caggaatgta cattctaaac aaaatagggg 2483
10 tttttaaggt atagtttttc aaaaacattt gggccataat ttattttctt ttaatgaata 2543
ctttttcatt tatattatat ttttcgtgta tatattttca ttatatacgt ttcattatat 2603
attatatatt tgtactatat atttttcatt tatatagttt tcattgtata ttatatacct 2663
15 cattatatta tataattcat tatatagttt tcatttaatt tatttcattt tataactaga 2723
acaatgaagc acagagaagt taagtaattt gcctaaggtc acacagctca ttgttgccct 2783
tagttcctgg cccatgctgc ttcccagtga atatgctaac aatgaatggg aaagggctctg 2843
20 ttaccagatt ggacttacat acttgaagcc aaacatgata gctcttgctc acatttaggc 2903
ctctttttat ccagttttcc tgacttgccg gagactctaa aaaaaaaaaa aaagggcggc 2963
25 cgc 2966

30 <210> 8
<211> 126
<212> PRT
<213> Homo sapiens

35 <400> 8
Met Leu Lys Ser Cys Ser Arg Ala Ser Phe Ser Pro Ser Val Arg Lys
1 5 10 15
Pro Pro Leu Ile Leu Arg Arg Leu Leu Ser Glu Asp Val Gly Met Asp
20 25 30
40 Ile Pro Phe Glu Glu Gly Val Leu Ser Pro Ser Ala Ala Asp Met Arg
35 40 45
Pro Glu Pro Pro Asn Ser Leu Asp Leu Asn Asp Thr His Pro Arg Arg
50 55 60
45 Ile Lys Leu Thr Ala Pro Asn Ile Asn Leu Ser Leu Asp Gln Ser Glu
65 70 75 80
Gly Ser Ile Leu Ser Asp Asp Asn Leu Asp Ser Pro Asp Glu Ile Asp
50 85 90 95
Ile Asn Val Asp Glu Leu Asp Thr Pro Asp Glu Ala Asp Ser Phe Glu
100 105 110
55 Tyr Thr Gly His Gly Lys Ser Leu Ser Trp Gln Gly Gln Ser
115 120 125

<210> 9
<211> 378
<212> DNA
5 <213> Homo sapiens

<220>
<221> CDS
<222> (1)..(378)
10
 <400> 9
atg ctg aag agc tgt agt cgt gca tcc ttc tca ccc tcc gtt aga aag 48
Met Leu Lys Ser Cys Ser Arg Ala Ser Phe Ser Pro Ser Val Arg Lys
 1 5 10 15
15
cct cct ctc atc ctc aga aga cta ctg tca gag gat gta gga atg gac 96
Pro Pro Leu Ile Leu Arg Arg Leu Leu Ser Glu Asp Val Gly Met Asp
 20 25 30
20
atc ccc ttt gaa gag ggc gtg ctg agt ccc agt gct gca gac atg agg 144
Ile Pro Phe Glu Glu Gly Val Leu Ser Pro Ser Ala Ala Asp Met Arg
 35 40 45
25
cct gaa cct cct aat tct ctg gat ctt aat gac act cat cct cgg aga 192
Pro Glu Pro Pro Asn Ser Leu Asp Leu Asn Asp Thr His Pro Arg Arg
 50 55 60
30
atc aag ctc aca gcc cca aat atc aat ctt tct ctg gac caa agt gaa 240
Ile Lys Leu Thr Ala Pro Asn Ile Asn Leu Ser Leu Asp Gln Ser Glu
 65 70 75 80
35
gga tct att ctc tct gat gat aac ttg gac agt cca gat gaa att gac 288
Gly Ser Ile Leu Ser Asp Asp Asn Leu Asp Ser Pro Asp Glu Ile Asp
 85 90 95
40
atc aat gtg gat gaa ctt gat acc ccc gat gaa gca gat tct ttt gag 336
Ile Asn Val Asp Glu Leu Asp Thr Pro Asp Glu Ala Asp Ser Phe Glu
 100 105 110
45
tac act ggc cat ggt aag tca cta agt tgg caa ggc caa agt 378
Tyr Thr Gly His Gly Lys Ser Leu Ser Trp Gln Gly Gln Ser
 115 120 125

What is claimed:

1. An isolated nucleic acid molecule selected from the group consisting of:
 - 5 (a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1;
 - (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3;
 - (c) a nucleic acid molecule comprising the nucleotide sequence set forth in
10 SEQ ID NO:4;
 - (d) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:6;
 - (e) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:7; and
 - 15 (f) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:9.
2. An isolated nucleic acid molecule which encodes a polypeptide selected from the group consisting of:
 - 20 (a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2;
 - (b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 5; and
 - (c) a polypeptide comprising the amino acid sequence set forth in SEQ ID
25 NO: 8.
3. An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number _____.
- 30 4. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2;
 - (b) a polypeptide comprising the amino acid sequence set forth in SEQ ID
35 NO: 5; and
 - (c) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8.

5. An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence which is at least 59% homologous to the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or a complement thereof;
 - b) a nucleic acid molecule comprising a fragment of at least 461 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9, or a complement thereof;
 - c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8; and
 - d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 5, or 8, wherein the fragment comprises at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2, 5, or 8.
6. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5 under stringent conditions.
7. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5.
8. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5, and a nucleotide sequence encoding a heterologous polypeptide.
9. A vector comprising the nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5.
10. The vector of claim 9, which is an expression vector.
11. A host cell transfected with the expression vector of claim 10.
12. A method of producing a polypeptide comprising culturing the host cell of claim 11 in an appropriate culture medium to, thereby, produce the polypeptide.
13. An isolated polypeptide selected from the group consisting of:

a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 5, or 8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, 5, or 8;

5 b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 5, or 8, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of SEQ ID NO:1, 3, 4, 6, 7, or 9 under stringent conditions;

10 c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 59 % homologous to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, or 9;

d) a polypeptide comprising an amino acid sequence which is at least 60% homologous to the amino acid sequence of SEQ ID NO:2, 5, or 8.

15 14. The isolated polypeptide of claim 13 comprising the amino acid sequence of SEQ ID NO:2, 5, or 8.

20 15. The polypeptide of claim 13, further comprising heterologous amino acid sequences.

16. An antibody which selectively binds to a polypeptide of claim 13.

25 17. A method for detecting the presence of a polypeptide of claim 13 in a sample comprising:

a) contacting the sample with a compound which selectively binds to the polypeptide; and

b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 13 in the sample.

30 18. The method of claim 17, wherein the compound which binds to the polypeptide is an antibody.

35 19. A kit comprising a compound which selectively binds to a polypeptide of claim 13 and instructions for use.

20. A method for detecting the presence of a nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5 in a sample comprising:

- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
- b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5 in the sample.

21. The method of claim 20, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

22. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of any one of claims 1, 2, 3, 4, or 5 and instructions for use.

23. A method for identifying a compound which binds to a polypeptide of claim 13 comprising:

- a) contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and
- b) determining whether the polypeptide binds to the test compound.

24. The method of claim 23, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detection of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay; and
- c) detection of binding using an assay for NIP2b, NIP2cL, or NIP2cS activity.

25. A method for modulating the activity of a polypeptide of claim 13 comprising contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

26. A method for identifying a compound which modulates the activity of a polypeptide of claim 13 comprising:

- a) contacting a polypeptide of claim 13 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

5

10

15

MNT061\APPLN.DOC

Input file 57h8Bcons; Output File 57h8Btra
Sequence length 3076

```
CCACGCGTCCGCCCACGCGTCCGGAAGAAGCAGCTACCTCGGAGGCAGGGCGCGCAGGCGGGCGGCGATGAGAGGGGG
CGCAGCCGCAGCCCCGCGCTGGGGAGCCCACCGCTAACCCCTGCACCCCACCCACCCCTGCACAAAAGAGCTGGCGGGCG
CTGGCCACGTGCCCCGCGGTGACCTTCCTCGGATGCAGAATCCGCCCCCTGCGAGCATCCTCTTCCTCCTAGGCTCTGAA
GGCCCGGGGAGCGTGAGCGATGCCAGCTGCACCCGGGCAGGGCTCGCCTTTGTTTGCCAGTAAGGAGGAGAGGCTGTC

                                     M   G   T   T   E   A
TCAGCTGCAGAGGGGTCCATCCCTGCTTCAAGCCAGTGCCTCTTCCCAGCTCCC ATG GGG ACC ACC GAA GCC

T   L   R   M   E   N   V   D   V   K   E   E   W   Q   D   E   D   L   P   R
ACG CTC CGG ATG GAA AAC GTG GAC GTG AAG GAG GAA TGG CAG GAC GAA GAT CTT CCC AGG

P   L   P   E   E   T   G   V   E   L   L   G   S   P   V   E   D   T   S   S
CCA CTC CCA GAA GAG ACG GGG GTG GAA CTG CTT GGC AGC CCG GTG GAA GAC ACA TCC TCT

P   P   N   T   L   N   F   N   G   A   H   R   K   R   K   T   L   V   A   P
CCT CCC AAC ACG CTA AAT TTC AAC GGA GCG CAT CGT AAG AGG AAG ACG CTG GTG GCC CCA

E   I   N   I   S   L   D   Q   S   E   G   S   L   L   S   D   D   F   L   D
GAG ATC AAC ATT TCT CTG GAT CAG AGT GAG GGG TCC CTG CTG TCC GAT GAC TTC TTG GAT

T   P   D   D   L   D   I   N   V   D   D   I   E   T   P   D   E   T   D   S
ACC CCT GAT GAC CTG GAT ATT AAC GTG GAT GAC ATC GAG ACC CCC GAT GAG ACC GAC TCG

E   F   L   G   N   G   N   E   L   E   W   E   D   D   T   P   V   A   T
CTG GAG TTC CTG GGG AAT GGC AAC GAA CTG GAG TGG GAA GAC GAC ACC CCC GTG GCC ACC

A   K   N   M   P   G   D   S   A   D   L   F   G   D   G   T   T   E   D   G
GCC AAG AAC ATG CCC GGG GAC AGC GCG GAT CTA TTT GGG GAC GGC ACG ACG GAG GAC GGC

S   A   A   N   G   R   L   W   R   T   V   I   I   G   E   Q   E   H   R   I
AGC GCC GCC AAC GGG CGC CTG TGG CGG ACA GTG ATC ATC GGG GAG CAA GAG CAC CGT ATA

D   L   H   M   I   R   P   Y   M   K   V   V   T   H   G   G   Y   Y   G   E
GAC CTG CAC ATG ATC CGG CCT TAC ATG AAA GTG GTC ACC CAC GGA GGG TAC TAC GGC GAA

G   L   N   A   I   I   V   F   A   A   C   F   L   P   D   S   S   L   P   D
GGC CTC AAC GCC ATC ATC GTC TTC GCA GCC TGC TTC CTT CCA GAC AGC AGC CTC CCC GAC

Y   H   Y   I   M   E   N   L   F   L   Y   V   I   S   S   L   E   L   L   V
TAC CAC TAC ATC ATG GAG AAC CTC TTC CTG TAC GTC ATC AGC AGC TTA GAG CTC CTG GTG

A   E   D   Y   M   I   V   Y   L   N   G   A   T   P   R   R   R   R   M   P   G
GCT GAG GAC TAC ATG ATC GTG TAC CTG AAC GGT GCC ACG CCC CGG CGG AGG ATG CCT GGA

I   G   W   L   K   K   C   Y   Q   M   I   D   R   R   L   R   K   N   L   K
ATC GGC TGG CTG AAG AAG TGC TAC CAG ATG ATC GAC CGG AGG TTG CGG AAA AAC CTG AAG

S   L   I   I   V   H   P   S   W   F   I   R   T   V   L   A   I   S   R   P
TCC TTG ATC ATC GTC CAC CCC TCG TGG TTC ATT CGG ACT GTG CTG GCC ATC TCT CGC CCT

F   I   S   V   K   F   I   N   K   I   Q   Y   V   H   S   L   E   D   L   E
ITC ATC AGC GTC AAG TTC ATC AAC AAG ATC CAG TAC GTG CAC AGC TTG GAA GAC CTG GAG

Q   L   I   P   M   E   H   V   Q   I   P   D   C   V   L   Q   Y   E   E   E
```

FIGURE 1

CAA CTC ATC CCT ATG GAA CAC GTC CAG ATC CCA GAC TGC GTC CTG CAA TAC GAA GAG GAA
 R L K A R R E S A R P Q P E F V L P R S
 AGA CTG AAG GCC AGG AGG GAG AGC GCG AGG CCC CAG CCG GAG TTT GTG CTG CCC AGG TCT
 E E K P E V A P V E N R S A L V S E D Q
 GAA GAG AAG CCA GAG GTG GCA CCA GTG GAA AAC AGG TCT GCT CTG GTC TCA GAA GAT CAG
 E T S M S *
 GAA ACA AGC ATG TCC TGA

GGCGACGTGAGCATAACAAAGGACATGGAAGAAGATTCCAGATGCCAGAAAACCTCTGTGACGCCCCACTGGCCCCAG
 ATCTCATCCTGCCTCATCCTGAGTCCCAATCTTCCAAGGGTGCCAGCCCCCTCCGTTTCATCTCTGAAACCCAGCATCCTT
 TTCAGCTGCTTGAAAACATTGTATTTTTTTTTTTTAAACGATGCAGTATTTGTGCGTTCCAGAAAAGGGCCCAGCTCTGA
 GCCCCCTACCCCTTCCACACTCACGAACTCTCAGCCGAGGAAGGCAAGAAGCGCAGGGGGTGGCCCCGCGTGGCGTCGGTG
 GCCTCCGCTCCTGCTCGCAGCCCCCTGTGGTCAGAGCTGGATACAAGATTCAAGACCCTTCTCTTGCTTGTACCCGCTC
 CAGGTTGGAGCCACAGACACCCACCGCCACCCCCGGCTGGGTCTGCGTCCTTTTCCTGTGCCTTTCCCTCCAGAATGCGGC
 CTCAGACCTAGAAGCTCAACCCCCCTATGAGGGCCACGTCCTGGGGTAGCTCCTGACCTCCGACCTTATGTCCAAATTT
 CACACCCATGGTTTTTTCATTTGACCCGCCCCCTTCTCGCTCATAATGACACCCAGCTCCTTTGAGAGGATCAGAGCCCCA
 TTGCACAAGAAGAGCCGCTGCCAACCATCCTTGTCTCCGATTGCAAAATGACACCCAGTAATCTAGAACATTCTCAA
 GCCCCTTTAACTCAGATGTCAAGCCACCGGGCAAACCCCGTCAATACCTCCCACCAAGGAATGAGATATGTGGACCTCA
 CTGCTCCCCCAACCCAGCGTCAGGCTGGGACACGCCAACGCTGTTCCGGGTTGGAACAGCACAGGCTCAGAAACTGGCT
 CTGAAATAGGCAGACCTAGCAAGAGGAAGATACAGGGTATCGGGCGTTTGTAGTGTTCAGAAGTCATTTCGGGAAGATAA
 ATCCAGTGCGCTGGCCGCAGCCACCTGCATTCAAAGCTTGGACCAGCGGGTTCTTGTTCGGGAGGCAAATTTCCCTAGG
 AAAAGAAGACAGACTTTTCTAATGGGGTCAAATGCGGATCACTGGTCAGATGGACTCTAGAAGCACTGAGCTCCCTG
 TCTCTGGAAGTATTTAAGAAAAGGCTGGGCCAGGCACGATGGCTCACGCCTGTAATCCCAGACTTTGGGAGGCCGAGGC
 AGGCGGATCACCTGAGGTGAGGAGTTTGAGAACAGCCTGGCCAACATGGTGAAACCTCATCTCTACTAAAAATACAAAA
 ATTAGCCAGGCGTGGTGGCAGGTGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCATGAGAATCACTTAAACCTGAGA
 GGCAGAGGTTACAGTGAGCCAAGATCGTGCCACTGCATTCCAGCCTGGGCGACAGAGCAAGACTCTGTCTCAAAAAAAA
 TAAAAAATAATCAGGGCACAGTGGCTCATGCCTGTAATCCCAGCACTCTGGGAGGCTGAGGTGGGTGGATCACCTGAGG
 TCAGGAGTTCAAGACCAGCCTGGTGAACATGGCGAAACCCCGTCTCTAATAAAAAATACAAAAATTAGCCGGGCATGGTG
 GTGCATGCCTG

FIGURE 1 (cont'd)




FIGURE 2

Input file Athda22f7.seq; Output File Athda22f7.tra
Sequence length 4235

```

          M E E E T E F L E L G T R I
GTCGACCCACGCGTCCGCGGAA ATG GAG GAG GAG ACA GAG TTC CTT GAG CTC GGA ACC AGG ATA

S R P N G L L S E D V G M D I P F E E G
TCA AGA CCA AAT GGA CTA CTG TCA GAG GAT GTA GGA ATG GAC ATC CCC TTT GAA GAG GGC

V L S P S A A D M R P E P P N S L D L N
GTG CTG AGT CCC AGT GCT GCA GAC ATG AGG CCT GAA CCT CCT AAT TCT CTG GAT CTT AAT

D T H P R R I K L T A P N I N L S L D Q
GAC ACT CAT CCT CGG AGA ATC AAG CTC ACA GCC CCA AAT ATC AAT CTT TCT CTG GAC CAA

S E G S I L S D D N L D S P D E I D I N
AGT GAA GGA TCT ATT CTC TCT GAT GAT AAC TTG GAC AGT CCA GAT GAA ATT GAC ATC AAT

V D E L D T P D E A D S F E Y T G H D P
GTG GAT GAA CTT GAT ACC CCC GAT GAA GCA GAT TCT TTT GAG TAC ACT GGC CAT GAT CCC

T A N K D S G Q E S E S I P E Y T A E E
ACA GCC AAC AAA GAT TCT GGC CAA GAG TCA GAG TCT ATT CCA GAA TAT ACG GCC GAA GAG

E R E D N R L W M T V V I G E Q E Q R I
GAA CGG GAG GAC AAC CGG CTT TGG ATG ACA GTG GTC ATT GGA GAA CAA GAG CAG CGC ATT

D M K V I E P Y R R V I S H G G D S G Y
GAC ATG AAG GTC ATC GAG CCC TAC AGG AGA GTC ATT TCT CAC GGA GGA GAT TCA GGA TAC

Y G D G L N A I I V F A A C F L P D S S
TAT GGG GAC GGT CTA AAT GCC ATC ATT GTG TTT GCC GCC TGT TTT CTG CCA GAC AGC AGT

R A D Y H Y V M E N L F L Y V I S T L E
CGG GCG GAT TAC CAC TAT GTC ATG GAA AAT CTT TTC CTA TAT GTA ATA AGT ACT TTA GAG

L M V A E D Y M I V Y L N G A T P R R R
TTG ATG GTA GCT GAA GAC TAT ATG ATT GTG TAC TTG AAT GGT GCA ACC CCA AGA AGG AGG

M P G L G W M K K C Y Q M I D R R L R K
ATG CCA GGG CTA GGC TGG ATG AAG AAA TGC TAC CAG ATG ATT GAC AGA CGG TTG AGG AAG

N L K S F I I V H P S W F I R T I L A V
AAT TTG AAA TCA TTC ATC ATT GTT CAT CCA TCT TGG TTC ATC AGA ACA ATC CTT GCT GTG

T R P F I S S K F S S K I K Y V N S L S
ACA CGA CCT TTT ATA AGT TCA AAA TTC AGC AGT AAA ATT AAA TAT GTC AAT AGC TTA TCA

E L S G L I P M D C I H I P E S I I N I
GAA CTC AGT GGG CTG ATC CCA ATG GAT TGC ATC CAC ATT CCA GAG AGC ATC ATC AAT ATT

D L K L K E K P *
GAC TTG AAG CTG AAA GAA AAG CCT TAG

```

```

TTGGCCATGCTGGAAGAAGAGGATGCTTTTCTGGTTCATGGTTCTGTTGAAACATATCTACCTGAAAGAGACAGGGCTG
ATGTTACCTTTTCCACTTTGCACTACCTGGTGCCATTCTAAATTTCTAAGGGGAAAAATAGAAAGTTTGTCTTACTCTT
AAGATATTTTATGAAATTGTGTGTACTTTCCTATTTTGCCAATTATGTGCCTCAAAGATTTTAGTTGAGCCTTAGCAAG

```

FIGURE 3

AAAGTAGGACCTTCCATTTCAATACTTCATTAACACGGTGTAGTGATACTTTGTCCCTTAGACTGGTGTTTACCAGTAA
 GATACCTTTAATCCACTGTAAAGTATGAGTGGATTTGTTTCCATAGATTAGCTGGATTTCCCTTTTGGTGATTGCATTAG
 GTTTAAAGTACACAGGTCTCAACTCTCCCCAGGAAAGTTTCCCCTGTTTGACTCCACCTTTAAATCCTAAGCCTGACT
 AGGACAGCCACAAACCACACAAGGTGTAAAACCATCATCAGCTAAGTGCCCGTTTTGTTCTTGTTTACCAGAATCTCCT
 TTAAGTTCTCAAAGGGAAGCCGGGCTTTCTAATCCACGTCAACTTTATTTTAGTTGTCAAATTGGGCATTATATTTTAT
 GTAAATTGGTCTTTTAAACATCATTTTCTGATGAATGTTGGTGACCACCACATTGTGAAATTTAAGAATCCGTGTTGCA
 TGTTTGGTAGCTCTCTGAGTTTCAGGCCATAAACTCAGCTCCAGAGGTTACCTTTTAAGTGCCAAGAAGTCAAGTGCAA
 GGTGGCCTACTCAAAAATCATTTGGTAGCATTTCAGTTATTTCATGAATTCCTCTCTCGCATGCATTATAAAAAGTGATCT
 GCTTTAAACACCCGTAATCTGATCATAGGCTTAAATTTAAATATGAGTATTACTTTTCATGTACAAAATATTTCTTTTAT
 AGTCTTCATATGCCCTTTAAATGCCAACAAGATTTCAAGTCTGTAGGCCTCTAGTGAGGTGGGGTGGCAAACCACAGC
 TAAGTCTCGCTCACCCTGCAAGCTAAGAATGGTTTTTTACATTTTGGGTGGAAAAATTTTTTTTGAATATTTTCATGAC
 ACATGAAAATTATTCAAATGTTAGTGCCGATAAATAAAGTGGTACTGAAACACAGCCACACAACTTGTTTTTGTACTG
 TGTACAGCTACTTTTCACTACAGCCGCAGAGCTGAGCAGTTTCAGCAGACCGTATGTCCCAATGCCTAAACATTGA
 CTATGTTTACAGAAAAAGTTTGCTGACCCCTGCTCTAGCAAACGCATCCTTTCTACTCCACCCCAATTTGTATTTAGA
 TAGTTTCTCTAACAGAACGGACAAATGAGGCTGCAACTAATTTATTTTTGTCAAAAATCAATGTTTGTGACATCCACAG
 ACAGTGAAATAAAAGAAATGGCTTGCTGAAAAACATGAGGAGTCTAGCCACAAAATCACTGCTTAGGTTGCAATTGCC
 AAAATGAAGCCTTCTTAGAAGCACTTCTTTAGTATATACAGGTGTTGGCTGAAGTCCGTGCCTCACTCTGGGAACCATT
 CTTAGTCTCCAGTGTCTCCTATTACAAAGAAGCTGGCAGAAATAAAATGAAGGGGTGAGAGCGGTTCACCCCTAGTCT
 CATGGTGGAAAAATTCATTGGGGAGAGCTGTCCAGGATATTTGGAGTCTGGGTAGAAGGAGCTTGTAAGTACTTTAAAG
 TCGACATCTTTGCACAGGTGATTGAGTTTCTCTGACCTCATTGCTTCACCTCTGTCTCCTCCCGTCTTCCGCACGTGC
 CCACACACACGCAGTTTCAGCCCTCTTTCTCCATAAGCCTCCATCGTTTTCTCTTTCTCCTCTTGATCCTTTCAAGCG
 AGTATCTTGTTGAATTGTATGTTCTGTTGGATCTCCTCCTTCATAACATCTGGCTTGTTGGACAGAAAAACCCTACAGC
 CCACCCCTCCACAGCCACCTCCACTTTTGAAAGCCCAAATTACACCTCTCCAGAACACAGTGTTGACGTAAATAC
 AGTTACCCAATATTCCTGTTTGTTCACCTATTTGCTACTTTCACTCAGTAGCATCCCATTTTGTAAAATGAATTCCATG
 GTCACCCTGTACAGGAAGTAATGAAAAATCCAGTGTTTCAGTGTTAGTGGTGCAAACCTGAGGGCATAGAGCTGTTTATA
 GAGGGCTCTTGTTATAGCCAAACAGACACAGCAACAATCTCACCATTATATATATATTTTTAACTTGTCAGCTCATC
 TATGGAAAATACTCAGGTGGTATGCTGTTTGAAGCCTCATCTTCTACATGAAAATTATGGGCATTGTCCCAATGAT
 TTTGTTTTCAGCTGTTCTGTAGGCTGCATAACCACTCTGATATTTAGGTATCTGCTATTTTATTATCTTAAAGACAAAT
 TAATTTAATTGCATGTGCTAGGGAAAAGCTACCATGTACATTCACCCCAAGTAAATAGAATCCTAGATGAATCCTAGAA
 AAATAATCCCTAAGCAGATAGGTAGACAGAGGTAAACATTTCATGATTTAGCTCTCTAGCTCTTGCACTCTGAACATT

FIGURE 3 (cont'd)

CTTGCTTTGGTTCTGACTTCTGGGAACTGCTTTGCATTTCTCCTATAGATCTGTAGTTAAGGGAACCAAGGGGTCATTG
GGGCAAAGCATTGTTTCTCAAAGCTCCTTGATTAAGAGAAAGAACAGAAATTTGCACAGAAGATAGTGTCAAGGAGTG
AGAAAGTTTGTTTGAGGGCAGTAGCTCAGTGTGGAAGAAAATCCTGAAGTTTCTGTTGAAGCCATACAATGTTCTATGG
GGTTACTCTCTAAGACATTCTCTGAGGTGTGTGAGGAAGTCACTACTCCTAGCCTTTGTTAAGATGTAATTTTAAATAT
TCAGTTATGGTACTATGTTTGCAACTCTCGTCTTATCACAATGCCTCAGTAGTTTGTTCCTTAGAAACATTTAGATGT
GCACAAATTAATCTTTTATATATCTAAAGGTTTTTCTATCATGCATTGGATTGCTCAGAATAAAGTGTCTGTTAGACTT
CGTTTTGGTAAATAAATTCTCCATAATGTAGATTAATAATATAAAAGTCTTTAATGACACAATATATCTATATAGCCTC
ACTGTATAATT CAGAAATAAAAATTGATTCTGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGCG
GCCGC

FIGURE 3 (cont'd)




FIGURE 4

Input file Alhbaa034f09.seq; Output File Alhbaa034f09.tra
Sequence length 2966

																		M	L	K	S	C	S			
GTCGACCCACGCGTCCGGGCGAATCTGTATTTCCAGTTAACTGCTCAGAAGAGAG																		ATG	CTG	AAG	AGC	TGT	AGT			
R	A	S	F	S	P	S	V	R	K	P	P	L	I	L	R	R	L	L	S							
CGT	GCA	TCC	TTC	TCA	CCC	TCC	GTT	AGA	AAG	CCT	CCT	CTC	ATC	CTC	AGA	AGA	CTA	CTG	TCA							
E	D	V	G	M	D	I	P	F	E	E	G	V	L	S	P	S	A	A	D							
GAG	GAT	GTA	GGA	ATG	GAC	ATC	CCC	TTT	GAA	GAG	GGC	GTG	CTG	AGT	CCC	AGT	GCT	GCA	GAC							
M	R	P	E	P	P	N	S	L	D	L	N	D	T	H	P	R	R	I	K							
ATG	AGG	CCT	GAA	CCT	CCT	AAT	TCT	CTG	GAT	CTT	AAT	GAC	ACT	CAT	CCT	CGG	AGA	ATC	AAG							
L	T	A	P	N	I	N	L	S	L	D	Q	S	E	G	S	I	L	S	D							
CTC	ACA	GCC	CCA	AAT	ATC	AAT	CTT	TCT	CTG	GAC	CAA	AGT	GAA	GGA	TCT	ATT	CTC	TCT	GAT							
D	N	L	D	S	P	D	E	I	D	I	N	V	D	E	L	D	T	P	D							
GAT	AAC	TTG	GAC	AGT	CCA	GAT	GAA	ATT	GAC	ATC	AAT	GTG	GAT	GAA	CTT	GAT	ACC	CCC	GAT							
E	A	D	S	F	E	Y	T	G	H	G	K	S	L	S	W	Q	G	Q	S							
GAA	GCA	GAT	TCT	TTT	GAG	TAC	ACT	GGC	CAT	GGT	AAG	TCA	CTA	AGT	TGG	CAA	GGC	CAA	AGT							

*
TAA

ATGCTAAATAAGTAAAAGATTTTCTAACAGACCTCTCATTTTTGTGCCAGTGGATCCTTTTTGTGATTTCTAGAAGCTT
GTGTTTTTATTTTCTAGGTTATAGGTGGCCATGATTGACAGTTTGGAGCCTGACAGAGAAAGTATGGGTACAGAGGCCAT
ACATAACCATTTGCTCTTTATTAACCCCCACTCTGTGCTAGCATTATGCTAGGCACTGGGGCTGAGGGAAGACTGTTAC
ATGCTGTGTTACAAGAAACCTGGGGCTGGGTTTGCAGGGGAAGAGAATTTAATCAGGATGATAAAATTTGAAGAAGAGA
AATCAGAGCTTGCCAATTTCTTGTTATAAGTTCCCACTATCTGCAATGTTCTTTTCCCCAGATCCTTACGTGACTGACTC
CTTCTCTTTATTTAGATGTTAATCAGATGTCACCTCCTCAGAGAAGTCTTCTTGACCTCTGTAATCAAAGATGCTTCC
CACTTCCCGACTCCCACCACCTAGTCACTCTCTGTCCCAGTGTTTATTTTATTTTCCACGTATCACTAATTCAAATTGT
ATTATTTAACTATTTGTTTGCATCTTTATTTCTCTTACCCTCGAATGTATGCTCCACAGGAGCAAGGACTTTA
TATTTGATCCTGCGTCTCCAATAAAGTGGAAGGAAGGAAGGGATGGTTTTAGGGGGAGTGAGAGAAATGATAAAAAAGA
AGATAATTAAAAGTTTTTCTAGATCATCAAGACTGACACTCCTGATATGAACTTCAGTCTTTCTTTAGTTCTTTCTCTTA
CTCTATGAAATCTGGTTTAAGAAATATGTACAAATACAATCATTTTTTTTTTAAATGGCATTATGTAGTTTCTGTTTCAG
TTCTAGCCAGGGTGGAATTCTCTGAAGTTATAATATTTGAAAGTGAAAGCGAGAGAGTCTGGGACACAGCTATTGCTTT
TATTCATTTTTTAAATTCACGCAATCTTAAAGCAATACAGTGCCACAATTAAGTGGTGGCCTGACTTTTAGAGACATG
CTAATTTCTAGCAGTTCCACTCCTAGAAGAGCATAATTAGAAAATTCACCAAATTAGCTAATTATTTCAACCAATGGTCA
TTGAGCCGACATGAGCAGTGCAGTTTCTAGACTCTACCTTGACAGAGCTTAAGGCTTTATTTTCTCAAAAAGGAAATGGCT
AAACGACTTGTTTTATAGTCTATTATGCTTAAGTAGAGTTTTTTTTTTTTTCCATAAGTTATTGGGGTACAGGTGGTATT
TGGTTACATGAGTAAGTTCTTTAGTGTAAGTAGAGATTTTATATTGCATTTTTATCATGTGTGAATTTCTGTAGTTATC

FIGURE 5

TGGGTAGTTGATTCTGTAGGTTGAAATACACAAATAGGAGGTGAAAGAAGGTCTGGAATTTGTACTATTTCTGTGCATC
CCAGAGAGTCTTCAGCAGCTCCTCTATCCATCCCAGTTGCCCCCTACCAGCTCCTGCTCCTTTCCCTGCTAATATATTG
ACCAAATCCCACAGAAGACTGTGGCATGACCCAACTGGCCCCCTCTCTGCTCCGGTATTTGCTTCCTTTTTGTGAGGA
GAGCTTTGTACACCACATCTGAACCTTTTATTTTTTAAACATAGTAAACTGTGAGCAAAGCAGTGGTGGCTGGGCAA
GCTGGTAATTAACACTGCCACTTGCTGACATGGCTCTTTTAATGTAGTTAACATAGCTGTGTTGAAAGAACCAGTTTAA
TGGCCACAACCCTGTTTTAGGTCTTAAATGCAAAGGACAGAATTGTAAACTAAGTTGAATTTTTTAAATCTACCTTAATT
TTCAAATGAAAGATATATAGTCAGAGGTTGAAACTTTGAAAACACAAAGTGCCTCTGAATAGCTATATTTTGTAACAT
GAGGACATGGATAAGTGACTGTATAAGAGGGTTGGATTATAAATATGTTTGAGTTCTGAAGTATGAAATAAAATGCTTGA
AAGCAGCCTGTTTCTTAGGTTTCTCACGCGACCATTTTGAACCAGGAATGTACATTCTAAACAAAATAGGGGTTTTTAA
GGTATAGTTTTTCAAAAACATTTGGGCCATAATTTATTTTCTTTTAATGAATACTTTTTCATTTATATTATATTTTTTCG
TGTATATATTTTCATTATATACGTTTCATTATATATTATATATTTGTACTATATATTTTTCATTTATATAGTTTTTCATT
GTATATTATATACCTCATTATATTATATAATTATTATATAGTTTTTCATTTAATTTATTTTCATTTTATAACTAGAACAA
TGAAGCACAGAGAAGTTAAGTAATTTGCCTAAGGTCACACAGCTCATTGTTGCCCTTAGTTCTGGCCCATGCTGCTTC
CCAGTGAATATGCTAACAATGAATGGGAAAGGGTCTGTTACCAGATTGGACTTACATACTTGAAGCCAAACATGATAGC
TCTTGCTCACATTTAGGCCTCTTTTTATCCAGTTTTCTGACTTGCGGGAGACTCTAAAAAAAAAAAAAAAAAGGGCGGCC
GC

FIGURE 5 (cont'd)




FIGURE 6

>PF00335|transmembrane4 4 transmembrane segments integral membrane proteins

Score: 1.28 Seq: 253 293 Model: 192 232
CMekIqdWlhnNfIIIagIciGIafIEilgMvFSMCLCRqI
C++ I+ L++N+ + +++ + +L ++ + +++I
human 253 CYQMIDRRLRKNLKSLIIVHPSWFIRTVLAI SRPFISVKFI 293

FIGURE 7

>MILPAT00063|calret_c calreticulin calcium-binding domain

Score: 0.66 Seq: 59 96 Model: 1 44

REF XX
YTIIYRPDNTFEVLIIDNWQVWSMSLETIWDMFLP.PDNPsREIeD

human 59 +T++ R + I ++ +S ++++D+ L+ PD EI D
DTHPRRIKL-TAPNINLSLDQSEGSILSDDN-LDSPD-----EI-D 96

FIGURE 9

GAP of: nip2b.pep check: 7307 from: 1 to: 371

NIP2B

to: nip2c.pep check: 3344 from: 1 to: 322

NIP2C Athda22f7

Symbol comparison table: /usr/local/gcg_9.1/gcgcore/data/rundata/blosum62.cmp
CompCheck: 6430

Gap Weight:	12	Average Match:	2.912
Length Weight:	4	Average Mismatch:	-2.003

Quality:	871	Length:	375
Ratio:	2.705	Gaps:	4
Percent Similarity:	69.182	Percent Identity:	58.805

Match display thresholds for the alignment(s):
| = IDENTITY
: = 2
. = 1

nip2b.pep x nip2c.pep

```
1 .MGTTEATLRMENVDVKEEWQDEDLPRPLPEETGVELLGSPVEDTSSPPN 49
  ||      :      ||.  :| || || | | : |||
1 MEEETEFLLELGTRISRPNGLLSEDVGMDIPFEEGV.LSPSAADMRPEPPN 49

50 TLNFGNAHRKRKTLVAPEINISLDQSEGSLLSDDFLDTPDDLIDINVDDIE 99
  .| . | | | :| | | ||| :||| ||| :||| ||| :||| :||| :|||
50 SLDLNDTHPRRIKLTAPNINLSLDQSEGSILSDDNLDSPDEIDINVDELD 99

100 TPDETDSLEFLGNGNELEWEDDTPVATAKNMPGDSADLFGDGTTEGSA 149
  |||| || | :| . || | | : : | | :
100 TPDEADSFEYTGHD.....PTANKDSGQSESESIPEYTAEERED 138

150 NGRLWRTVIIGEQRIDLHMIRPYMKVVTHG...GYGEGLNAIIVFAA 196
  | ||| ||| :||| ||| : . | || : : . | | ||| :||| ||| |||
139 N.RLWMTTVVIGEQRIDMKVIEPYRRVISHGGDSGYGDGLNAIIVFAA 187

197 CFLPDSSLPDYHYIMENLFLYVISSLELLVAEDYMIVYLNATPRRRMPG 246
  ||||| ||| :||| ||| :||| :||| :||| :||| :||| :|||
188 CFLPDSSRADYHYVMENLFLYVISTLELMVAEDYMIVYLNATPRRRMPG 237

247 IGWLKKCYQMIDRRRLRKNLKSIIIVHPSWFIRTVLAISRPFISVKFINKI 296
  :||| :||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
238 LGWMKKCYQMIDRRRLRKNLKSFIIVHPSWFIRTVLAISRPFISVKFINKI 287

297 QYVHSLEDLEQLIPMEHVQIPDCVLQYEEERLKRRESARPQPEFVLPRS 346
  .||| .||| :| | ||| : : ||| : : : . .
288 KYVNSLSELSGLIPMDCIHIPESIINIDLKLKEKP..... 322
```

FIGURE 11

GAP of: nip2c.pep check: 3344 from: 1 to: 322

NIP2C Athda22f7

to: nip2a.pep check: 3241 from: 1 to: 314

NIP2A | U15173 Homo sapiens BCL2/adenovirus E1B 19kD-interacting protein 2 (BNIP 2)

Symbol comparison table: /usr/local/gcg_9.1/gcgcore/data/rundata/blosum62.cmp
CompCheck: 6430

Gap Weight:	12	Average Match:	2.912
Length Weight:	4	Average Mismatch:	-2.003

Quality:	806	Length:	331
Ratio:	2.567	Gaps:	6
Percent Similarity:	67.541	Percent Identity:	57.705

Match display thresholds for the alignment(s):

| = IDENTITY
: = 2
. = 1

666707 264460

nip2c.pep x nip2a.pep

```
1 MEEETEFLELGTRISRPNGLLSEDVGMDIPFEEGVLSPSAADMPE.PPN 49
      : || . : | : : . | || |
1 .....MEGVELKEEWQDEDFPIPLPEDDSIEADILAITGPEDQPG 40
50 SLDLNDTHPRRIKLTAPNINLSLDQSEGSILSDDNLDSPDEIDINVDELD 99
||:| : || |||.|.||| :||:|||| ||| |||: |||
41 SLEVNGNKVRK.KLMAPDISLTLDPSDGSVLSDD.LDESGEIDL..DGLD 86
100 TPDE.ADSFEYTGHDPTANKDSGQSESIPEYTAEEEREDNRLWMTVVIG 148
|| | .. ||: | || |||| ||| |||: || | |||
87 TPSENSNEFEWEDDLPKPKTTEVIRKGSITEYTAAEEKEDGRRWRMFRIG 136
149 EQEQRIDMKVIEPYRRVISHGGDSGGYGDGLNAIIVFAACFLPDSSRADY 198
||: | :||| |||: :||| | ||||| |||: || | :||. .|
137 EQDHRVDMKAIEPYKKVISHG... GYYGDGLNAIIVVFAVCFMPRESSQPNY 183
199 HYVMENLFLYVISTLELMVAEDYMIVYLNATPRRRMPGLGWMKKCYQMI 248
|. :||| ||| |||: |||.||| |||: || | |||: ||| |
184 RYLMDNLFKYVIGTLELLVAENYMIIVYLNATTRRKMPSLGWLKCYQQI 233
249 DRRLRKNLKSFIIVHPSWFIRTLAVTRPFISSKFSSKIKYVNSLSELSG 298
||||||| ||| ||||| |||: ||||| ||||| |||: || |. ||.
234 DRRLRKNLKSIIIVHPSWFIRTLAVTRPFISSKFSQKIRYVFNLAELAE 283
299 LIPMDCIHIPESIINIDLKLEKP..... 322
|: ||: | ||| | :| . |
284 LVPMEYVGIPKQVDQELNGKQDEPKNEQ 314
```

FIGURE 12

Customer Number: 000959

Attorney's

Docket

Number MNI-061

Declaration, Petition and Power of Attorney for Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ISOLATED PROTEINS AND NUCLEIC ACID MOLECULES HAVING
HOMOLOGY TO THE NIP2 PROTEIN AND USES THEREOF

the specification of which

(check one)

X is attached hereto.

__ was filed on _____ as

Application Serial No. _____

and was amended on _____

(if applicable)

I do not know and do not believe that the subject matter of this application was known or used by others in the United States or patented or described in a printed publication in any country before my invention thereof, or patented or described in a printed publication in any country or in public use or on sale in the United States more than one year prior to the date of this application, or first patented or caused to be patented or made the subject of an inventor's certificate by me or my legal representatives or assigns in a country foreign to the United States prior to the date of this application on an application filed more than twelve months (six months if this application is for a design) before the filing of this application; and I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

CLAIM OF BENEFIT OF EARLIER FOREIGN APPLICATION(S)

I hereby claim priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application(s) for patent or inventor's certificate filed by me on the same subject matter having a filing date before that of the application(s) from which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____	_____
(Application Serial No.)	(Filing Date)

_____	_____
(Application Serial No.)	(Filing Date)

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any earlier United States application(s) or PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the earlier application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date(s) of the earlier application(s) and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier application(s), if any, described below, I do not know and do not believe that the same was known or used by others in the United States or patented or described in a printed publication in any country before my invention thereof, or patented or described in a printed publication in any country or in public use or on sale in the United States more than one year prior to the date(s) of said earlier application(s), or first patented or caused to be patented or made the subject of an inventor's certificate by me or my legal representatives or assigns in a country foreign to the United States prior to the date(s) of said earlier application(s) on an application filed more than twelve months (six months if this application is for a design) before the filing of said earlier application(s); and I acknowledge that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented,pending,aband.)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

W. Hugo Liepmann	Reg. No. 20,407	Lawrence E. Monks	Reg. No. 34,224
James E. Cockfield	Reg. No. 19,162	David A. Lane, Jr.	Reg. No. 39,261
Thomas V. Smurzynski	Reg. No. 24,798	Catherine J. Kara	Reg. No. 41,106
Ralph A. Loren	Reg. No. 29,325	Scott D. Rothenberger	Reg. No. 41,277
Thomas J. Engellenner	Reg. No. 28,711	Linda M. Chinn	Reg. No. 31,240
Giulio A. DeConti, Jr.	Reg. No. 31,503	Kevin J. Canning	Reg. No. 35,470
Ann Lamport Hammitte	Reg. No. 34,858	Faustino A. Lichauco	Reg. No. 41,942
Elizabeth A. Hanley	Reg. No. 33,505	C. Eric Schulman	Reg. No. 43,350
John V. Bianco	Reg. No. 36,748	Jeanne M. DiGiorgio	Reg. No. 41,710
Amy E. Mandragouras	Reg. No. 36,207	Megan E. Williams	Reg. No. 43,270
Anthony A. Laurentano	Reg. No. 38,220	Nicholas P. Triano III	Reg. No. 36,397
Jane E. Remillard	Reg. No. 38,872	Peter C. Lauro	Reg. No. 32,360
Jeremiah Lynch	Reg. No. 17,425		

all of: LAHIVE & COCKFIELD, LLP, 28 State Street, Boston, MA 02109

and to: Robert A. Millman	Reg. No. 36,217	Jean M. Silveri	Reg. No. 39,030
Mark F. Boshar	Reg. No. 35,456	Theodore Allen	Reg. No. 41,578
Cynthia Kanik	Reg. No. 37,320		

of: Millennium Pharmaceuticals, Inc., 238 Main Street, Cambridge, MA 02142-1017

Send Correspondence to Amy E. Mandragouras at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109

Direct Telephone Calls to: Amy E. Mandragouras, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Rory A.J. Curtis	
Inventor's signature	Date
Residence 31 Constitution Drive, Southborough MA 01772	
Citizenship British	
Post Office Address (if different)	

Full name of sole or first inventor M. Alexandra Glucksmann	
Inventor's signature	Date
Residence 33 Summit Road, Lexington, Massachusetts 02173	
Citizenship Argentina	
Post Office Address (if different)	